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ABSTRACT 
 
Introduction 
Rheumatoid Arthritis (RA) is a chronic, inflammatory, autoimmune disorder characterized by inflammation of 
the joints and surrounding tissue causing pain, swelling and stiffness. Studies suggest that aspects of the 
diet may alleviate symptoms and decrease the risk of complications. The scientific basis for a role of dietary 
therapy in RA has grown although there is still no consensus on the optimum diet. It has been shown that 
persons with RA tend to have a poor nutritional status; and rheumatoid cachexia, the loss of body cell mass, 
occurs in nearly two-thirds of all patients with RA. The study aimed to establish what RA patients are 
practicing and their perceptions regarding the effect of diet, nutritional supplements, medication and 
complementary and alternative medicines (CAM) and therapies on their symptoms as well as determining 
their body composition and the possible presence of rheumatoid cachexia.  
Methodology 
The study design was a cross-sectional study with an analytical component. The study population consisted 
of adult (18 years or older) RA patients in the Cape Metropole from the private and public sector. An 
interviewer-administered questionnaire was used followed by the measurement of weight, height, waist 
circumference and skinfold thickness. Information was also gathered from the medical records. 
Results 
The sample size comprised of 251 RA patients (n=201 public sector; n=50 private sector). The mean body 
mass index (BMI) was 30.3 kg/m2 for females and 26.6 kg/m2 for males. BMI was used to classify obesity 
(n=133; 45.9%), overweight (n=66; 26.8%), normal weight (n=63; 25.6%) and underweight (n=4; 1.6%). 
Waist circumference measurement classifications showed a substantially increased risk for metabolic 
complications in 51.8% of participants (n=127) and an increased risk in 21.2% of participants (n=52). Just 
over half of the participants (n=65; 55.6%) had an unhealthy high body fat percentage classification. 
Rheumatoid cachexia was seen in 10.3% participants (n=12). Low fat-free mass (Fat-free mass index <10th 
percentile) was seen in 21% participants (n=24) and obesity (Fat mass index >90th percentile) was seen in 
27% of participants (n=31). Twenty nine percent of participants (n=73) believed that certain types of food 
could improve their symptoms of RA and 60% of participants (n=151) believed that certain foods worsened 
their symptoms. Sixty four percent of participants (n=161) thought that nutritional supplements or 
complementary and alternative medicines and therapies could improve their symptoms of RA and 98% 
(n=246) of participants used nutritional supplements. The most frequently used supplements included folic 
acid (n=218; 91.6%), calcium (n=182; 76.5%), vitamin D (n=185; 77.7%), omega-3 fatty acids (n=48; 64.9%) 
and multivitamin and mineral preparations (n=22; 29.7%). 
Conclusion 
The obesity and waist circumference figures were unacceptably elevated in this population and the body 
composition of these RA patients should be highlighted as a concern. The high prevalence of risk factors for 
cardiovascular disease (CVD) need to be urgently addressed since CVD is the leading cause of mortality in 
RA patients. This study highlights the important role of the intra-professional team, including the dietitian, in 
the management of RA patients. 
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OPSOMMING 
Inleiding 
Rumatoïede artritis (RA) is 'n chroniese, inflammatoriese, outo-immuun siekte wat gekenmerk word deur 
inflammasie van die gewrigte en omliggende weefsel en veroorsaak pyn, swelling en styfheid. Studies dui 
daarop dat aspekte van die dieet simptome kan verlig en die risiko van komplikasies kan verminder. Die 
wetenskaplike basis vir die rol van dieetterapie in RA het gegroei, hoewel daar nog geen konsensus  
aangaande die optimale dieet is nie. Dit is al bewys dat persone met RA  geneig is om 'n swak voedingstatus 
te hê; en rumatoïede cachexia, die verlies van  liggaam selmassa  in byna twee-derdes van alle pasiënte 
met RA voorkom. Die doel van die studie was om te bepaal  wat RA-pasiënte se praktyke  en  persepsies 
ten opsigte van die uitwerking van dieet, voedselaanvullings, medikasie en aanvullende of  alternatiewe 
medisyne (CAM) en terapieë op hul simptome het, sowel as om hul liggaamsamestelling en die moontlike 
teenwoordigheid van rumatoïede cachexia te bepaal.  
Metodiek 
Die studie ontwerp was 'n dwarssnitstudie met 'n analitiese komponent. Die studiepopulasie het bestaan uit 
volwassene (18 jaar of ouer) RA pasiënte uit die privaat en openbare sektore in die Kaapse Metropool. 
Onderhoude was gevoer met behulp van vraelyste. Gewig, lengte, middelomtrek en velvoudikte was ook 
gemeet. Inligting was ook versamel uit mediese rekords. 
Resultate 
Die steekproefgrootte het uit 251 RA pasiënte (n=201 openbare sektor, n=50 privaat sektor) bestaan. Die 
gemiddelde liggaamsmassa-indeks (LMI) was 30.3 kg/m2 vir vroue en 26.6 kg/m2 vir mans. LMI was gebruik 
om vetsug te klassifiseer (n=133; 45.9%), asook oorgewig (n=66; 26.8%), normale gewig (n=63; 25.6%) en 
ondergewig (n=4; 1.6%). Klassifikasie van middelomtrek metings het 'n aansienlike verhoogde risiko vir 
metaboliese komplikasies in 51.8% van die deelnemers (n=127) en 'n verhoogde risiko in 21.2% van die 
deelnemers (n=52) getoon. Net meer as die helfte van die deelnemers (n=65; 55.6%) het 'n ongesonde hoë 
liggaamsvet persentasie klassifikasie getoon. Rumatoïede cachexia was by 10.3% van die deelnemers 
(n=12) gevind. Lae vetvrye massa (vetvrye massa indeks <10de persentiel) was by  21% deelnemers (n=24) 
en vetsug (vet massa indeks >90ste persentiel) in 27% van die deelnemers (n=31) teenwoordig. Nege-en-
twintig persent van die deelnemers (n=73) het geglo dat sekere voedselsoorte hul simptome van RA kon 
verbeter en 60% van die deelnemers (n=151) was van mening dat sekere kosse die simptome kon vererger. 
Vier-en-sestig persent van die deelnemers (n=161) het gedink dat voedingsaanvullings of aanvullende en 
alternatiewe medisyne en terapieë hulle simptome van RA kon verbeter en 98% (n=246) van die deelnemers 
het voedingsaanvullings gebruik. Die mees algemene gebruikte aanvullings was foliensuur (n=218; 91.6%), 
kalsium (n=182; 76.5%), vitamien D (n=185; 77.7%), omega-3 vetsure  (n=48, 64,9%) en multi-vitamien en 
mineraal preparate (n=22; 29.7%). 
Gevolgtrekking 
Die vetsug en middelomtrek syfers was onaanvaarbaar verhoog in die studiepopulasie en die 
liggaamsamestelling van hierdie RA pasiënte  is 'n bekommernis. Die hoë voorkoms van risikofaktore vir 
kardiovaskulêre siekte (KVS) moet dringend aangespreek  word, aangesien die KVS  die grootste oorsaak 
van sterfte in RA pasiënte is. Hierdie studie beklemtoon die belangrike rol van die intra-professionele span, 
met inbegrip van die dieetkundige, in die bestuur van  RA pasiënte. 
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CHAPTER 1: LITERATURE REVIEW AND MOTIVATION FOR STUDY 
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1.1 INTRODUCTION 
Rheumatoid Arthritis (RA) is known to be a chronic, inflammatory, autoimmune disorder 
characterized by inflammation of the joints and surrounding tissue causing pain, swelling and 
stiffness.1,2  As the disease progresses, if left untreated, it may eventually result in damage to the 
joints and permanent disability.2 The synovium of the joint is the site of onset of joint deterioration 
and is characterized by a large number of proliferating T-lymphocytes, marked immunoglobin 
production, and increased inflammatory cytokine production. The inflammatory cytokines, tumor 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1), are believed to play central roles in the 
pathogenesis of RA.2 
 
1.1.1 Prevalence 
In South Africa, the latest prevalence rates of persons with RA were found to be 408,533 in 2003,3 
it affects ~ 0.5 - 1% of the population worldwide and is three times more common in women than in 
men.1,2,4.5,6 The peak incidence of onset occurs between the fourth and sixth decades of life.7 
 
1.1.2 Diagnosis and Symptoms 
The diagnosis of RA is primarily clinical, but also relies on laboratory tests such as serum 
rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) and typical 
radiographical changes as seen on an x-ray.8 Anti-CCP antibodies tend to be more specific but 
equally as sensitive as RF and are of value in the diagnosis of early RA and in predicting joint 
damage and is currently used in combination with RF for an improved accurate diagnosis. The 
1987 American College of Rheumatology (ACR) criteria for classification of RA (Table 1.1) is 
usually used as entry criteria for clinical trials, but can also guide a clinician with an assessment. 
The patient must have at least four of the seven criteria and criteria 1 to 4 must be present for at 
least 6 weeks.1,8 
 
Table 1.1 Summary of 1987 ACR classification criteria for RA5,8 
Summary of 1987 ACR classification criteria for RA 
1. Morning stiffness at least 1 hour 
2. Arthritis of three or more joints 
3. Arthritis of hand joints 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Abnormal serum RF 
7. Typical radiographic changes 
ACR= American College of Rheumatology; RF= rheumatoid factor; RA= Rheumatoid Arthritis 
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Symptoms of RA include symmetrical pain, tenderness and swelling of the affected joints with 
morning stiffness, afternoon fatigue and malaise, anorexia, weakness, and occasionally low-grade 
fever.1 The joints involved include the following: wrists and the index and middle 
metacarpophalangeal joints (most commonly involved), proximal interphalangeal joints, 
metatarsophalangeal joints, shoulders, elbows, hips, knees and ankles.1,8 (Figure 1.1) 
 
Figure 1.1. Illustration of the joints commonly affected in Rheumatoid Arthritis.9 
 
1.1.3 Aetiology and Risk Factors 
RA is a multi-factorial disease of unknown aetiology resulting from the interaction of genetic and 
environmental factors.4,10 Due to the difference seen in prevalence between men and women, an 
influence of reproductive and hormonal factors is suggested but it is unclear how gender influences 
the occurrence of RA.4,5 Infectious agents may also be involved in the occurrence of RA, however, 
this role also remains unclear.4,5 Smoking may influence the risk of developing RA as well as the 
course of the disease and an increased risk for seropositive disease is related to smoking 
habits.4,5,11 Socioeconomic factors such as occupation, educational level, marital status, and social 
group appear to influence the course and the outcome of RA rather than the risk of developing RA 
and available data suggests an association of poor socioeconomic status with a worse 
prognosis.4,5,12 It has also been shown that obesity is associated with the development of RA.5 Diet 
may have a role to play in that several studies have suggested a potential protective effect of oily 
fish, olive oil, and vegetables. The protective role of fish consumption has been attributed to the 
effect of omega-3 fatty acids (FA). The Mediterranean diet has also been reported as a lifestyle 
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factor which may reduce the risk of developing RA and protects against the severity of the course 
of disease.4,5,13,14 
 
1.1.4 Co-morbidities 
1.1.4.1 Cardiovascular disease and osteoporosis in rheumatoid arthritis 
An increased risk of cardiovascular disease (CVD) exists among patients with RA, especially those 
with seropositive RA.15 The exact reasons for this increased risk of heart disease is unclear but is 
likely to relate to certain traditional and novel risk factors. The traditional risk factors include a 
consistent finding among RA patients of low levels of high-density lipoprotein (HDL) cholesterol 
and higher levels of small, dense low-density lipoprotein (LDL) cholesterol which is known to be 
more atherogenic than regular LDL cholesterol.15 A study conducted by Brady et al16 showed that 
compared to controls, RA subjects were more likely to smoke (p<0.001), be physically inactive 
(p=0.006), and have higher mean measurements of body mass index (p=0.040) and waist 
circumference (p=0.049). They found that the mean absolute risk of CVD was higher in the RA 
group, even after excluding smokers (p = 0.036).16 
 
The novel risk factors include systemic inflammation and while traditional cardiovascular risk 
factors appear to play an important role, they do not fully explain the increased risk of CVD in RA. 
Inflammation is common to both CVD and RA and there are similarities between the inflammatory 
responses seen in atherosclerosis and RA. Furthermore, the association between RA and CVD 
might also be attributable to the atherogenic side effects of corticosteroids and selective 
cyclooxygenase-2 inhibitors, which are commonly used in RA.15,16 Significantly lower levels of 
serum antioxidants carotenoids (β-cryptoxanthin, α-carotene, lycopene and lutein/ zeaxanthin) and 
significantly higher C-reactive protein (CRP) levels have also been shown in RA cases compared 
to controls, and this too has been proposed as a novel risk factor for CVD in RA, although it is 
uncertain whether low serum carotenoid levels explain the increased incidence of CVD in RA.17,18 
In another study, compared to healthy controls, older women with RA had poor vitamin B6 status 
and elevated plasma homocysteine concentrations and this could also contribute to an increased 
risk of cardiovascular disease.19 
 
Osteoporosis is a complication of RA that results in increased risk of fractures and is associated 
with resultant morbidity, mortality, and increased healthcare costs.18,20 Bone metabolism in RA is 
altered by the chronic inflammatory process via the activation/inhibition of bone cell function, 
modification of body composition, corticosteroid use, diet and low levels of physical activity. 
Furthermore, elevated levels of inflammatory cytokines during the active phase of the disease lead 
to reductions in fat-free mass with a loss of body cell mass and consequent reduction in muscle 
strength.21 This loss may negatively affect bone mineral density due to the fact that lean mass is a 
predictor of bone mass through its mechanical pull on the skeleton.22 Corticosteroid treatment in 
RA also induces osteoporosis by decreased calcium absorption, increased renal calcium excretion 
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and inhibition of oestrogen production in women, with direct and indirect effects on osteoblast and 
osteoclast function.22,23 Corticosteroids result in low bone mass by directly affecting osteoblastic 
activity and hence, reducing bone formation that predominantly affects the trabecular bone. It is 
well known that long-term use of glucocorticoids increases the risk of all osteoporotic fractures and 
it is therefore recommended that the use of more than 5 mg prednisolone for three months or 
longer requires careful vigilance with regular investigation and subsequent treatment in order to 
prevent osteoporosis.24 
 
1.1.5 Prognosis  
The disease progresses rapidly during the first 6 years, particularly during the first year and 80% of 
patients develop some permanent joint abnormalities within 10 years. The course of the disease is 
unpredictable in individual patients.1 RA patients have a higher mortality rate than the general 
population and according to the disease severity and the age of disease onset, their survival is 
expected to decrease by three to ten years.1,4 The leading cause of mortality is cardiovascular 
disease, and other causes include infection, gastro-intestinal bleeding, respiratory disease, and 
several malignancies.4,25 Reasons for the increased mortality are likely to be multifactorial and may 
include the effects of chronic inflammation, disability, and co-morbidity as well as the effects of 
concurrent  immunosuppressive therapy. The results of previous studies have however suggested 
that mortality may be improved by the control of inflammation with methotrexate, a disease 
modifying anti-rheumatic drug (DMARD).25 Approximately 10% of RA patients are eventually 
severely disabled despite full treatment. Caucasians and the female sex seem to have a poorer 
prognosis, as well as those with subcutaneous nodules, advanced age at the onset of disease, 
inflammation in more than 20 joints, early erosions, cigarette smoking, high erythrocyte 
sedimentation rate, and high levels of RF or anti-CCP.1 
 
1.1.6 Effect of Rheumatoid Arthritis on Quality of Life 
Quality of life can be defined as “the extent to which an individual is able to meet his/her needs”.26 
The goals of treatment of RA are to reduce symptoms and improve functional status by limiting 
disease activity and improving quality of life. Consequences of the disease include loss of 
employment, reduced social functioning and significant healthcare costs.27 Although arthritis is not 
considered as a major health problem; it is the highest cause of physical disability in the United 
Kingdom (UK), affecting 8.2% of the UK population. Challenges that RA patients are faced with 
include the unpredictability of the disease coarse, uncertain prognosis and the physical, 
psychological and social functioning impact of the disease.27,28 A study conducted in China showed 
that depression and anxiety were common in patients with RA and patients who lacked social 
support or relied on economic assistance were more prone to the development of psychiatric 
disorders.29 Another study conducted in the United States (US) also showed a strong association 
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of depression with functional severity in RA patients.30 The pain and disability caused by RA 
certainly has a significant negative effect on the quality of life of people living with RA.27 
 
1.1.7 Economic Burden of Rheumatoid Arthritis 
The economic burden of RA is thought to be substantial for people with RA as well as the relevant 
health services.31 A systematic review31 reported that the mean annual direct costs associated with 
RA were US$5720 and the mean annual indirect costs were US$5822. The mean costs for out-
patient visits were US$1855 and US$4944 for in-patient stays.31 The percentage of RA patients 
that were hospitalized ranged from 12% to 26% and for all studies, except two, in-patient costs 
were found to be the largest constituent of the total annual medical costs associated with RA.31 
Indirect costs relating to the number of days absent from work per annum due to RA ranged from 
2.7 days/year to 30 days/year per patient.31 
 
A study conducted in the US showed that the use of biologic therapy (a relatively expensive new-
line cytokine inhibitor or receptor site antagonist treatment) for RA was sensitive to the benefit 
generosity of the patient’s health insurance plan as well as their household financial burden.32 They 
found that RA patients on plans with less generous coverage of biologic therapies were less likely 
to commence a biologic therapy and were more likely to discontinue its use. They also found that 
individuals in households with high financial burden of health care expenses are also less likely to 
initiate a biologic therapy.32 
 
1.2 MANAGEMENT 
 
1.2.1 Medical Management 
A rheumatologist is the primary physician in treatment but other health care practitioners, such as 
nurses, physical therapists, dietitians, occupational therapists, social workers, psychologists and 
orthopaedic surgeons also play an important role in the management of RA and provision of 
supportive care.33 
 
1.2.1.1 Non-pharmacological treatment 
Non-pharmacological treatment involves educating the patient and their family about the disease 
and about becoming involved in the decision making process with regard to the course of 
treatment.33 Rest and exercise may help to maintain joint mobility and reduced stress and a 
healthy diet may also be beneficial in treating RA.33 
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1.2.1.2 Pharmacological treatment 
Pharmacologic treatment of RA involves the use of various medications such as analgesics, non-
steroidal anti-inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs (DMARDs), 
corticosteroids and biologic DMARDs.1  
 
1.2.1.3 Management strategies 
Studies have shown that early aggressive management of RA provides better outcomes in terms of 
quality of life and disability.8,34 The goal of an aggressive treatment strategy in RA is to modify the 
natural course of the disease which will lead to alleviating pain, reducing inflammation and the risk 
of structural damage, improving functional status and quality of life and preventing joint deformity 
and disability.8,34 In achieving the treatment goals it is important to determine the most effective 
combination of pharmacologic therapy, which may include NSAID, DMARD(s), low-dose 
prednisone, local injection of glucocorticoid, rehabilitation support, and analgesics.33 Current 
treatment guidelines highlight the use of DMARDs early in the disease within 3 months of 
diagnosis.34 The arrival of newer treatments and strategies such as biologic agents, the use of 
combination DMARD therapy and the resurgence of low-dose corticosteroid therapy have been 
shown to improve outcomes in clinical trials.34 The use of DMARD combination therapy or 
DMARD(s) plus a biologic agent with or without low-dose corticosteroids is now used relatively 
commonly in current clinical practice.34  
 
1.2.1.4 Non-steroidal anti-inflammatory drugs 
NSAIDS such as aspirin and ibuprofen relieves pain, improves joint function and reduces 
inflammation.3,33 It however does not reduce joint destruction and has serious gastrointestinal (GI) 
side effects such as nausea, vomiting, diarrhoea, GI bleeding and peptic ulcers.33 Peptic ulcers 
may cause malabsorption of certain nutrients.35 NSAIDS may also cause renal damage and 
controversies exist regarding the possible increase in cardiovascular morbidities, more significant 
with cyclo-oxygenase-2 (COX-2) selective blockers.8 Choosing a NSAID which is appropriate for 
the individual involves considering effectiveness of the drug, safety, convenience and costs.33 The 
mechanism of action of NSAIDS involves the inhibition of cyclo-oxygenase (COX) of which there 
are two types, namely COX-1 and COX-2, and thus decrease production of prostaglandins. Some 
prostaglandins under COX-1 control have important effects such as the protection of gastric 
mucosa. Selective COX-2 inhibitors seem to have efficacy comparable to non-selective NSAIDs 
and are less likely to cause GI damage; however, they do not seem less likely to cause renal 
toxicity. Although COX-2 inhibitors have a significantly lower risk of gastrointestinal damage than 
other NSAIDS, they are not more effective and are much more expensive than non-selective 
NSAIDS.1,33 
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1.2.1.5 Disease modifying anti-rheumatic drugs 
DMARDS are used as the main treatment of RA and Methotrexate (MTX) is widely considered the 
cornerstone of RA treatment and may be used as monotherapy or in combination with other 
agents. MTX is a folate antagonist with immunosuppressive effects at high dose and has anti-
inflammatory effects at the doses used in RA.1 MTX is frequently the first DMARD prescribed 
subsequent to the diagnosis of RA, and a significant proportion of patients respond favourably to 
MTX monotherapy.8,36 It is one of the most effective DMARDs in reducing signs and symptoms, 
disability and structural damage along with less toxicity and improved tolerability.37,38 MTX alone 
however may not fully control disease activity in some patients and is increasingly being used in 
combination with other DMARDs. A recent systematic review showed that there is no statistically 
significant advantage of MTX combination therapy versus monotherapy. However, significant pain 
reduction and improvement in physical function were found in the MTX combination group in 
patients with inadequate MTX response.37 Another recent systematic review suggests the early 
use of conventional DMARDs with escalation to biologic agents only for patients who have 
responded inadequately to conventional DMARDS.36 Although the development of biologic agents 
has revolutionized the treatment of RA, they have not necessarily replaced the role of conventional 
DMARDs. MTX remains the cornerstone of nearly all anti-rheumatic regimens, whether they 
include synthetic or biologic DMARDs or not. Combination therapy with conventional DMARDs 
may well be as effective as therapy with biologics and is associated with a significantly lower 
cost.36 Other conventional DMARDS used in the treatment of RA include Hydroxychloroquine, 
Leflunomide and Sulfasalazine and immunosuppressive immunomodulatory or cytotoxic DMARDS 
include Azathioprine Cyclophosphamide Cyclosporine.1,36 
 
1.2.1.6 Glucocorticoids 
Glucocorticoids at low doses (<10 mg/day prednisone) and local injections of glucocorticoids are 
very effective for relieving symptoms in patients with active RA.33 They appear to have disease 
modifying effects by slowing down the rate of joint damage. Evidence exists that low-dose 
glucocorticoids can significantly reduce the rate of erosions in early RA and their addition to 
standard therapy can be beneficial in the short term. Long-term continuous use beyond 4 years is 
however not indicated because of their serious side effects such as osteoporosis, hypertension, 
weight gain, fluid retention, hyperglycaemia, cataracts and skin fragility. Theses side effects should 
be taken into consideration when deciding to administer glucocorticoids.8,33 
 
1.2.1.7 Biologic disease modifying anti-rheumatic drugs 
Biologic DMARDs are a new type of therapy which has developed during the past decade due to 
an increasing knowledge of the pathogenesis of RA and have revolutionized the management of 
RA.36,39,40 Their considerable economic impact and long-term safety concerns have however 
excluded their routine use at the onset of disease before traditional DMARDs are attempted.8 The 
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most commonly used biologic agents are TNF-α inhibitors such as Etanercept, Adalimumab, 
Infliximab, Golimumab and Certolizumab. Tocilizumab is an IL-6 receptor antagonist and Rituximab 
is an anti-B-cell biologic agent. Anakinra (an IL-1 receptor antagonist) and Abatacept (a selective 
co-stimulation modulator that blocks the interaction between T lymphocytes and antigen-presenting 
cells) are not recommended by the National Institute for Health and Clinical Excellence (NICE) for 
the treatment of RA.8 When compared with TNF-α inhibitors, Anakinra has shown less benefit in 
clinical outcomes and frequent injection site reactions. It is seldom used now, because of the 
availability of better therapies.8 Several studies have shown that TNF-α inhibitors are highly 
effective in decreasing the risk of joint damage with a rapid onset of action, especially when 
combined with MTX in patients who have not responded well to traditional DMARDs. They also 
improve physical function and quality of life. There is however a lack of head-to-head comparison 
studies among the different types of biologics but indirect comparison in systematic reviews does 
not show substantial differences in efficacy among them, although there are some differences in 
their toxicity profiles.8 Choosing between different biologic agents is usually based on their safety 
profile, routes of administration, costs, health insurance coverage and patient preferences. 
Biologics are much more costly than traditional DMARDs due to the higher cost of production and 
the development of the complex proteins and antibodies.8,40   
 
1.2.1.8 Drug-nutrient interactions 
Drug-nutrient interactions are commonly overlooked when physicians prescribe drugs and as more 
pharmaceutical agents become available, attention should be focused on the interactions of drugs 
with certain food and nutrients.41 Drugs can have an effect on nutritional status by altering nutrient 
absorption, metabolism, utilization or excretion and, on the other hand, food, beverages and 
vitamin or mineral supplements can have an effect on the absorption and effectiveness of drugs.41 
Patients at risk of developing drug induced deficiencies are those whose diets are inadequate, 
those who have increased nutritional needs such as pregnant or lactating women and children, the 
elderly, persons with chronic illnesses, those who are on long term medication and those who 
abuse substances such as alcohol and recreational drugs.42 It is important that a well balanced diet 
is eaten to ensure that these drug-induced deficiencies do not occur. 
 
1.2.1.8.1 Aspirin and Ibuprofen 
Studies have shown that aspirin may block vitamin C from being transported to cells but the 
importance of this interaction is not known. With large doses of aspirin, folic acid levels decrease 
and iron levels may also drop due to small amounts of blood which are lost due to GI bleeding 
when aspirin is taken. These small losses over time may lead to an iron deficiency. It is 
recommended that the intake of foods rich in vitamin C, folic acid and iron should be increased or 
supplementation of these nutrients can be prescribed.43,44,45 Common nutritional side effects of 
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these drugs include nausea, vomiting, GI bleeding and constipation. It is advised to avoid GI 
irritants such as pepper, caffeine and alcohol with long term use.43 
 
1.2.1.8.2 Methotrexate 
This drug affects the lining of the GI wall and may cause malabsorption of vitamin B12 and β-
carotene and is said to be a folate antagonist. MTX binds to dihydrofolate reductase and prevents 
the conversion of folic acid and dihydrofolate to its active form, tetrahydrofolate, which is required 
for purine synthesis.41 MTX also causes nausea and vomiting, diarrhoea, anorexia and GI distress. 
It is recommended that an intake of foods rich in these nutrients should be included in the diet. A 
supplement should be considered if signs of deficiency of these nutrients should appear.1,43,44,46 
 
1.2.1.8.3 Azathioprine 
Azathioprine may cause symptoms of nausea, vomiting and anaemia. Depletion in folic acid and 
vitamin B12 levels may occur. Supplementation may therefore be required. An increased fluid 
intake may also be needed.43 
 
1.2.1.8.4 Cyclosporine 
This drug may cause nausea, vomiting, GI distress, diarrhoea and hyperkaleamia. It is suggested 
that a low fat, low potassium diet be followed.43 
 
1.2.1.8.5 Penicillamine 
Penicillamine may not be optimally absorbed if taken simultaneously with iron or magnesium. It is 
therefore recommended to only eat foods rich in magnesium and iron, as well as supplements 
which contain magnesium and iron, several hours after this medication has been taken. This 
medicine may also cause a depletion of zinc and copper levels. A high dietary intake or 
supplementation of these minerals can be considered.44,45 This drug can also cause altered taste, 
nausea, vomiting, diarrhoea and loss of appetite.45 
 
1.2.1.8.6 Corticosteroids 
Corticosteroids can deplete the body’s vitamin D stores, impair calcium absorption from the GI and 
impair calcium metabolism and long-term use may eventually result in bone loss and 
osteoporosis.33,45,46 
 
1.2.1.9 Biologic disease modifying anti-rheumatic drugs and effect on body composition 
It is not yet known what the effect of the new biologic agents is on body composition. A study by 
Serelis et al47 showed no significant changes on body composition and lumbar spine bone mineral 
density in women with RA after 1 year of anti-TNF treatment.47 Metsios et al48 also did not show 
any significant changes in fat free mass after 12 weeks of anti-TNF-therapy.48 A study conducted 
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by Engvall et al49 however showed  that patients who received anti-TNF treatment had a significant 
increase in fat mass at 2 years of 3.8 kg (1.6 to 5.9), in contrast to patients treated with 
sulphasalazine and hydroxychloroquine [0.4 (-1.5 to 2.2) kg (P = 0.040)], despite similar disease 
activity reduction. Both treatment strategies prevented loss of muscle mass and bone. Infliximab 
therapy increased body fat mass, which was an effect that was not achieved with the combination 
of traditional DMARDs, despite a similar reduction in disease activity, and thus seems to be drug 
specific.49 There is a need for longer-term studies in this field in order to determine whether or not 
biologics indeed cause an increase in body fat and if so, close attention needs to be paid to this as 
being overweight not only increases the risk of cardiovascular disease further but also puts extra 
strain on the joints. 
 
1.2.1.10 Surgery 
Surgical treatment of RA can be considered when levels of pain are unbearable or loss of joint 
function has occurred. Carpal tunnel release, synovectomy, metatarsal head resection, total joint 
anthroplasty and joint fusion are surgical procedures which can be done.33 
 
1.2.1.11 Current management practices in South Africa 
In Cape Town, the public sector tertiary facilities use analgesics such as Paracetamol, alone or in 
combination with codeine and in severe cases with Tramadol. NSAIDS such as Diclofenac and 
Ibuprofen are widely used. Disease modifying agents such as Methotrexate (with folate 
supplementation), Azathioprine, Chloroquine, Cyclphosphamide and Cyclosporin are also used. 
Steroids are used short term and in combination with calcium and vitamin D supplements. 
Biological agents are not used often as the budgets do not permit it. In the primary health care 
clinics, Paracetemol and Ibuprofen are mainly used also due to budget constraints. In the private 
sector, the use of biologics is employed if all other treatment options have failed in providing relief 
from symptoms. [Personal communication: Dr H Reuter (2010) and Dr D Whitelaw (2010)]  
 
1.2.2 Exercise and Physical Therapy 
Regular aerobic and resistance activity does not necessarily decrease inflammation in RA, but has 
been shown to improve range of joint movement and strength and endurance. It also helps to 
preserve bone mass and lean body mass and prevents fatigue and depression. It is also said to 
improve the distribution of forces of muscle contraction more evenly over the joint surfaces.9 
Regular exercises, physical therapy and occupational therapy can help in symptomatic and 
functional improvement.8 Exercise is a non-pharmacological intervention effective in managing 
fatigue for some people with RA and a systematic review found that low-impact aerobics, walking, 
cycling, and jogging were effective interventions.50 Exercise has become an essential part of the 
rehabilitation of patients with RA during recent years, and the benefits of both aerobics and hand-
strengthening exercises have been reported. Studies have shown that daily hand exercise is 
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effective in increasing hand grip strength. A recent study showed a significant improvement in hand 
force and hand function in patients with RA after 6 weeks of hand training and the improvement 
was even more marked after 12 weeks. Hand exercise is thus an effective intervention for 
rheumatoid arthritis patients, leading to better strength and function.51 
 
Dynamic exercise programmes (DEPs) studies have provided evidence for quality of life 
improvement and have shown an improvement in Health Assessment Questionnaire (HAQ) 
measurement in the DEP group.52 Joint rehabilitation constitutes the cornerstone of physical 
therapy and DEPs are now being used for the rehabilitation of RA patients. There is no 
standardized design of DEP for patients suffering from RA, but most of the programmes follow the 
American College of Sports Medicine for healthy individuals’ recommendations. These 
recommendations state that exercise must lead to a 60% increase of predicted maximal heart rate 
for 20 minutes, at least twice a week to show improvement of muscular strength and aerobic 
capacity.52 Previous studies also support the evidence for improvement of aerobic fitness and 
muscle strength after exercise interventions in RA. It has been shown that this type of intervention 
has positive consequences on aerobic fitness with excellent compliance.52 Randomised controlled 
trials (RCT) have shown that joint specific dynamic exercises may improve strength and physical 
function in RA, but without a clear effect on pain or disease activity. The optimal exercise 
programmes however still need to be determined.53 
 
Progressive Resistance Training (PRT) significantly increases muscle mass and muscle growth 
and restores physical function in patients with RA.54,55 A study recently confirmed that PRT is a 
safe and effective means of restoring muscle mass and functional capacity in patients with stable 
RA and concluded that PRT programs should be included in disease management.54,55 Pending 
confirmation of these results in a larger randomized controlled trial that includes a wider range of 
RA patients with more active and severe disease, PRT programs should be included in the 
management of RA as well as an adjunct treatment for rheumatoid cachexia.55 
 
Yoga is another type of exercise which has been studied and a small study found that it may 
decrease the HAQ disability index, decrease the perception of pain and depression and improve 
balance.56 Yoga involves rotating joints through their full range of motion which increases flexibility. 
Standing poses promote balance by strengthening and stabilizing muscles to reduce falls. Yoga 
therefore incorporates several elements of exercise that may be beneficial for RA.57  
 
1.2.3 Occupational Therapy 
The main goals of occupational therapy in RA are to decrease pain, prevent deformity, improve 
function and promote participation.58 One recent RCT and a Cochrane review reported a positive 
effect of occupational therapy on functional ability and self management, but without an effect on 
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disease activity.59,60 Work disability is a serious adverse outcome of RA.61 Occupational therapists 
have a key role to play in assisting people to remain working by enhancing functional ability. Timely 
comprehensive occupational therapy can significantly improve functional and work-related 
outcomes in employed patients with RA who are at risk of work loss. A significant improvement in 
physical function, work productivity and coping indicates that even if the disease severity remains 
unchanged, a positive effect on work participation is accomplished by influencing environmental 
factors.62 
 
1.2.4 Complementary and Alternative Medicines (CAM) 
The use of complementary and alternative supplements and practices has become a growing and 
ever more popular field, especially within population groups suffering from a chronic disease.63 
Research has shown that 60%–90% of persons with arthritis use CAM and the main reason given 
for its use was to overcome pain.64-68 A survey in America found that about two thirds of RA 
patients used some form of complementary or alternative therapy such as chiropractic, 
acupuncture, supplements and special diets.65 Supplements and herbal treatments for the 
treatment of RA are vast and include to name a few Glucosamine, Chondroitan, Gamma Linolenic 
Acid, Thunder God Vine and Plant-Mineral Preparations. Therapies include Acupuncture, 
Hydrotherapy and Homeopathy.69 
 
There is a large variety of complementary and alternative treatments available on the market and 
the majority of these products do not distinguish between osteoarthritis and rheumatoid arthritis in 
their marketing and on the labels. Patients often use these treatments as it is generally believed 
that they are “safer” and more “natural” than conventional medications.69 These treatments can 
however in some cases even be dangerous. For example, while Tripterygium wilfordii (Chinese 
herb known as Thunder God Vine) may have beneficial effects on the symptoms of RA, it is 
associated with serious adverse effects such as impaired renal function, haematotoxic and 
immunosuppressive effect, hair loss, diarrhoea and nausea. The Royal Australian College of 
General Practitioners (RACGP) guidelines for management of early rheumatoid arthritis state that 
this Chinese herb must not be recommended to RA patients.70 Extensive research with regard to 
safety, effectiveness and dose required must still be conducted before many of the above 
mentioned products should be allowed to target and be advertised to a population with a chronic 
disease such as RA.69 
 
1.2.4.1 Alternative supplements 
1.2.4.1.1 Glucosamine and chondroitan 
Glucosamine sulphate (recommended at a dosage of 1,500mg/day), extracted from chitin from 
crab, lobster or shrimp shells, is a precursor to the glycosaminoglycan molecule used by the body 
to form and repair cartilage. Chondroitin sulphate (recommended at a dosage of 1,200mg/day), an 
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extract from cattle tracheas and shark cartilage, is the most abundant glycosaminoglycan in 
cartilage and is responsible for its elasticity. These substances may be taken in a supplement 
together or apart. Glucosamine has undergone many clinical trials in the field of osteoarthritis and 
was previously shown to be effective with regard to alleviating pain and narrowing joint space after 
a period of six to eight weeks. However a meta analysis conducted in 2010 showed that, compared 
with placebo, glucosamine, chondroitin, and the combination of the two does not reduce joint pain 
or have an impact on the narrowing of joint space in osteoarthritis.71 A small recent study on 
glucosamine-chondroitin-quercetin glucoside supplement on the synovial fluid properties of 
patients with osteoarthritis and rheumatoid arthritis showed no benefit in the RA patients.72 More 
research must be done with regard to the effects of these supplements on rheumatoid arthritis and 
at this stage cannot be recommended to patients with RA.65,73 
 
1.2.4.1.2 Gamma linolenic acid 
Gamma Linolenic Acid (GLA) is advertised to have anti-inflammatory effects. It is found in evening 
primrose oil (2% GLA), blackcurrant seed oil (6% GLA) and borage seed oil (9% GLA), and has 
been found to improve joint tenderness, morning stiffness, swelling and pain in a number of 
studies.69,70,74 The RACGP guidelines for management of early rheumatoid arthritis provides a 
grade C recommendation for its use at a dosage of 1400 mg/day of GLA or 3000 mg/day of 
evening primrose oil.70 (Table 1.2) 
 
Table 1.2. Royal Australian College of General Practitioners (RACGP) recommendation 
grading70 
A. Excellent evidence – body of evidence can be trusted to guide practice 
B. Good evidence – body of evidence can be trusted to guide practice in most 
situations 
C. 
Some evidence – body of evidence provides some support for recommendation(s) 
but care should be taken in its application 
D. 
Weak evidence – body of evidence is weak and recommendation must be applied 
with caution 
 
1.2.4.1.3 Plant-mineral preparations 
Ayurvedic plant-mineral preparations, RA-1 and RA-11, often containing ingredients such as 
ginger, curcumin (an extract of turmeric), boswellia (Indian frankincense) and feverfew (a botanical 
folk medicine), are used to apparently “provide significant pain relief and improvement of objective 
signs of pain and inflammation.” A small clinical trial was conducted on feverfew and reported no 
beneficial difference in results between the placebo and feverfew. Ginger was found to increase 
the side effects of NSAID’s and creates blood-thinning effects. All components were reported to 
cause side effects such as nausea, diarrhoea and stomach upset.69,75 
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1.2.4.2 Alternative therapies 
1.2.4.2.1 Acupuncture 
Acupuncture, originally a Chinese practice, is “the stimulation of anatomical points on the body by 
a variety of methods, including the insertion and manipulation of thin needles or the use of 
pressure from the practitioner’s hands.”69 Very few appropriate studies have been done on the 
effectiveness for the relief of symptoms of RA. This treatment is generally safe, however it is 
advised that patients should only be treated by licensed practitioners.69 
 
1.2.4.2.2 Hydrotherapy 
Hydrotherapy is the use of water for therapeutic purposes. A few examples of hydrotherapy include 
bathing in heated water, for example hot springs or the sea; mineral baths; and water-jet 
massages. A recent systematic review69 has shown that there is improvement of symptoms with 
this therapy however the safety of hydrotherapy has not been well studied. Hygiene and irritants to 
substances in the water should be monitored. Overall, it appears to be a low-risk practice for most 
people. However, hydrotherapy is riskier and could even be dangerous for people whose condition 
could be worsened by exposure to extremes of heat or cold or by strong motions from water jets.69 
Hydrotherapy in RA has been evaluated in two recent meta-analyses [reported in the European 
League Against Rheumatism (EULAR) report53] with positive findings but there is insufficient 
evidence to support a strong recommendation. More research on this therapy is needed.53 
 
1.2.4.2.3 Homeopathy 
Homeopathy, developed in Germany, is the practice based on the theory of “giving very small 
doses of substances called remedies that would produce the same or similar symptoms of illness 
in healthy people when given in larger doses.”69 Little rigorous research has been done on 
homeopathy for RA and has shown positive and negative results with regard to effectivity. Most 
remedies are considered safe.69 
 
1.2.5 Dietary Management 
1.2.5.1 Dietary manipulation 
Studies suggest that aspects of the diet may alleviate symptoms, combat the side-effects of 
therapy and decrease the risk of complications.46,76,77,78 The possible benefits may be due to 
altered gut flora, a reduced permeability to bacteria and other antigens, altered antioxidant levels, 
weight loss and the elimination of offending foods.46,76,77,78 The improved symptoms seen in clinical 
studies may also be due to the change from an unhealthy diet to a healthier diet involving an 
increased fruit and vegetable consumption and a reduction in saturated fats.77 The effects of 
dietary manipulation require further randomized, long-term studies to confirm the benefits of 
specific diets in order to make specific recommendations.77 It has been reported that 33% to 75% 
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of RA patients believe that food plays an important role in the severity of their symptoms and 20% 
to 50% have tried to manipulate their diet in order to relieve their symptoms.14 
 
The scientific basis for a role of dietary therapy in RA has grown in the last few years although 
there is still no consensus on the optimum diet. The abnormal regulation of the cytokines TNF-α 
and IL-1 have been identified as primary factors in the pathogenesis of RA and this has provided 
the rational for the use of dietary treatment in the form of the so-called “anti-inflammatory diet”.14 
Current literature states that no specific food group has been proven to reduce or increase 
symptoms of RA because the evidence is inconclusive. A diet high in red meat, dairy, cereals, 
citrus, chocolate, alcohol and spices has been said to have adverse effects for some RA sufferers, 
but as of yet, there is no solid evidence proving this statement correct.14,45 Food members of the 
nightshade family including tomatoes, white potatoes, eggplant and peppers have also been 
believed to have adverse effects for RA sufferers. Also, some suggested foods that have 
supposedly positive effects on RA include Brewer’s yeast, apple cider vinegar, honey, wheat germ, 
molasses, ginger and garlic. There is however no solid evidence proving that any of these foods 
has a definite effect on RA symptoms.45,75 This subject is however controversial as patients’ 
reactions to specific foods are highly individualized especially if a food allergy or intolerance is 
present and this point must be emphasized.14  
 
1.2.5.2 Food allergies or intolerances 
Food allergies or intolerances to various food items such as dairy products and cereals have been 
reported in several RA case studies and in all reports the removal of the specific food type resulted 
in a favourable response and on reintroduction of the food into the diet, developed symptoms 
again.14 It has been recommended that if a patient feels he/she has a reaction to a specific food, or 
that food seems to worsen or alleviate symptoms of RA, then the patient should avoid or increase 
(in moderation) consumption, respectively, of that particular food group.45,75 
 
A study by Karatay et al79 linked food allergy testing and cytokines and found that 13 out of 20 RA 
patients with a positive skin prick test experienced disease exacerbations in clinical symptoms and 
experienced increased levels of TNF-α, IL-1, and C-reactive protein with food allergen challenges. 
The authors therefore put forward that food allergy triggers, rather than acts, as a causative 
agent.79 The link between food allergy or food intolerance and joint complaints is particularly 
referred to when patients with a known food allergy and intolerance are concerned. Food is the 
greatest source of exposure to foreign antigens. The literature suggests that food allergy or 
intolerance appears to play a role in only a small proportion of rheumatic patients.42 This implies 
that it is unnecessary to put all people with chronic joint symptoms on a strict diet. When the 
medical history suggests possible food intolerance, further investigations need to be carried out 
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and an elimination diet and an open or double-blind challenge test are the only way to identify both 
the affected patients and the offending foods.42  
 
1.2.5.3 Types of diets 
A systematic review by Smedslund et al80 describes the common diets used by people with RA 
which include vegetarian or vegan, Mediterranean, elemental and elimination diets.80 Vegetarian 
diets exclude all meat and vegan diets (which exclude all animal products) are higher in 
antioxidants and this may be a factor in reducing pain and stiffness. The Mediterranean diet is high 
in fruit, vegetables, cereals and legumes; low in red meat; and high in fish and olive oil. This diet’s 
possible protective effect could be due to the high levels of unsaturated fats and antioxidants.80 An 
elimination diet involves the removal of one or more potentially offending foods one at a time and 
then gradually reintroducing them to determine whether any of them aggravates symptoms. The 
elimination diet is based on the principle that food antigens potentially play a role in the 
pathogenesis of a disease and that its elimination from the diet should result in the improvement of 
symptoms.80 The elemental diet is believed to be hypoallergenic and consists of amino acids, 
glucose, medium-chain triglycerides, vitamins, and minerals. It is industrially premade, packaged in 
sachets and is used as a meal replacement for one or more meals per day.80 
 
Results from trials with moderate risk of bias indicate that fasting followed by a vegetarian diet as 
well as fasting followed by a Mediterranean diet may improve symptoms of pain in RA patients 
when compared to an ordinary diet.80 No effects were seen however in physical function, stiffness, 
or other important outcomes. Although some studies have reported improvements in some 
symptoms of RA, the definite mechanisms of action are still not unequivocally known. When 
looking at the common denominators for most of the diets, there is an increase in fruits, vegetables 
and fibre, a reduction in saturated fat, and energy restriction. And as discussed earlier, this results 
in altered antioxidant levels, resultant weight loss, and the removal of allergies/intolerances and 
changing from an unhealthy to a healthier diet could explain some of the positive changes seen in 
the RA symptoms.77,80 
 
Dietary manipulation may improve symptoms in some RA patients, but these diets are often 
associated with a high dropout rate.77 A very important issue when looking at the dietary 
management of RA patients is that many of the patients may already be nutritionally compromised 
due to a number of reasons discussed in sections 1.2.1.8 and 1.5 . Smedslund et al80  describe 
that it is therefore very important to weigh up the benefits and harm of very restrictive diets such as 
the vegan, elimination and elemental diets as these patients are especially vulnerable to the 
adverse effects of diet restrictions.80 Dietary manipulation is not appropriate for everyone, 
especially those who are at nutritional risk. The palatability and strict regimens of some of these 
eating plans leads to a reduced dietary intake and a very serious consequence of diet manipulation 
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is that one or more food groups are eliminated from the diet which may lead to the risk of nutritional 
deficiencies of key nutrients.80 For example, without specialized diet and meal planning, a strict 
vegan diet could cause a deficiency in protein and several vitamins and minerals. Another 
important aspect to take into consideration is that a strict dietary program not only affects nutrition, 
but is also difficult to maintain in terms of social life where a special diet must be catered for.80 The 
most important aspect in dietary manipulation is that the safety is uncertain and must not be 
recommended or practiced without consulting a registered dietitian. On the other hand, a diet such 
as the Mediterranean diet is nutritionally adequate and well balanced and includes moderate 
amounts of lean meat, unsaturated fats replacing saturated fats, plenty of fruits, vegetables and 
fish. It is also recommended for people with heart disease and osteoporosis, and RA patients are 
at risk of developing both conditions.80 
 
1.2.5.4 Supplementation 
1.2.5.4.1 Omega-3 fatty acid supplementation 
It has been shown in many studies that supplementation with fish oil, rich in omega-3 fatty acids 
(FA), reduces inflammatory markers and decreases the need for NSAIDS and DMARDS.81,82,83 
Anti-inflammatory doses range between 2.6g/day and 7.1g/day with an average of 3.5g/day of 
omega-3 FA supplements in the form of eicosapentanoic acid and docosahexanoic acid.14,81 The 
RACGP guidelines for management of early RA provides a grade A recommendation (Table 1.2) 
for omega-3 supplementation as an adjunct for management of pain and stiffness in patients with 
RA.70 A recent meta-analysis81 of 17 studies involving 823 patients showed significant effects for 
four out of six pain outcomes including patient assessed pain (Standardized Mean Differences 
(SMD): -0.26; 95% CI: -0.49 to -0.03; p=0.03), morning stiffness (SMD: -0.43; 95% CI: -0.72 to -
0.15; p=0.003); number of painful and/or tender joints (SMD: -0.29; 95% CI: -0.48 to -0.10; 
p=0.003); and NSAID consumption (SMD: -0.40; 95% CI: -0.72 to -0.08; p=0.01). Significant 
effects were however not detected for physician assessed pain and the Ritchie articular index 
which is used to calculate a disease activity score (DAS). Eleven of the 16 studies used high doses 
(above 2.7 g omega-3 FA per day) and significant improvements were noted in patient assessed 
pain and morning stiffness in the studies providing high dose, but not low dose, omega-3 FA. 
These results suggest a role for high dose omega-3 supplements as adjunctive treatment for the 
pain and stiffness associated with RA. 81 
 
While omega-3 FA stimulates the production of anti-inflammatory compounds, omega-6 FA 
stimulates the production of pro-inflammatory compounds. Mono-unsaturated FA reduces the 
competition for absorption between omega-3 FA and omega-6 FA and therefore increases the 
uptake of omega-3 FA into the cell membranes.46 Omega-9 FA (oleic acid), in olive oil, also 
competes with omega-6 FA for absorption.46 The decrease in absorption of omega-6 FA will 
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therefore decrease the undesired pro-inflammatory effects in RA.46 Data on the optimal omega-6 
FA to omega-3 FA ratio in RA is scarse.  
 
1.2.5.4.2 Micronutrient supplementation 
Based on the low antioxidant status of persons with RA shown in studies, claims have been made 
that micronutrient supplementation may be beneficial in the dietary treatment of RA.45,84 Selenium, 
Zinc, Magnesium, Niacin and beta-carotene have been identified to potentially have beneficial 
effects.85 However, results of clinical trials have been disappointing with no significant anti-
inflammatory effects being shown with antioxidant supplementation compared to a placebo in 
studies done with high doses of vitamin E and selenium.86,87 It has been suggested that a 
supplement with a combination of several antioxidants may be more effective than a single 
antioxidant supplement as they are known to work synergisitically.85 The first double blind, placebo 
controlled study to investigate whether or not a combination of polyunsaturated fatty acids (PUFA) 
and micronutrients indeed does have a positive effect on tender joint count, was done but no 
significant differences were found.85  
 
Folate supplementation has been shown to decrease the toxicity and mucosal and GI side effects 
of MTX which is known to be a folate antagonist.46,88 It has also been shown to improve the 
continuation of MTX therapy by reducing the incidence of liver function test abnormalities and GI 
intolerance. Furthermore, supplementation with folic acid compensates for the elevation in plasma 
homocysteine associated with the use of MTX and this may in turn decrease the risk of 
cardiovascular disease which is known to be present in persons with RA and for which 
hyperhomocysteinaemia is now recognized as an independent risk factor for cardiovascular 
disease. Routine folic acid supplementation should be prescribed to all patients receiving MTX and 
a dose of 5 mg oral folic acid given on the morning following the day of MTX administration is 
recommended. Folate supplements do not appear to significantly reduce the effectiveness of MTX 
in the treatment of RA.89 
 
RA patients with documented osteoporosis or those at high risk for the development of 
osteoporosis should receive calcium and vitamin D supplementation as well as an anti-resorptive 
agent.90 In selected patients with RA who are at high risk of vitamin D deficiency, correction of 
deficiency may be important in both the management of osteoporosis and decreasing the risk of 
falls and fractures. Vitamin D supplementation in this patient group may also reduce RA disease 
activity although there is currently a lack of studies to prove this.91 Vitamin D supplementation in 
RA reduces bone loss, and the combination of vitamin D and calcium supplementation significantly 
reduces fracture rates.92 The recommendations for vitamin D supplementation to correct deficiency 
and manage osteoporosis includes bolus oral dosing of 100 000U vitamin D, together with daily 
oral vitamin D tablets (with or without calcium supplementation), with monitoring and repeat dosing 
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at regular intervals.91 The ACR recommends that patients receiving glucocorticoids should receive 
calcium and vitamin D supplementation for any dose or duration of glucocorticoids. Calcium intake 
with oral intake plus supplementation should reach 1200 to 1500mg/day. Vitamin D 
supplementation should aim to achieve therapeutic levels of 25-hydroxyvitamin D, or dosages of 
800 to 1000 IU/day are two dosing regimens which could be utilized. It should also be taken into 
account though that glucocorticoids can interfere with vitamin D absorption and may require a 
higher supplementation dose to achieve therapeutic levels.93 
 
1.3 NUTRITIONAL REQUIREMENTS 
1.3.1 Energy Requirements 
The impact of the inflammatory process differs from person to person and activity levels may also 
vary greatly. This, therefore, makes it difficult to establish specific energy requirements for persons 
with RA. Energy intake should be sufficient to achieve or maintain an ideal body weight. The Harris 
Benedict equation, a formula used to calculate energy requirements, with a stress factor of 1.14-
1.35 (to compensate for the effects of hypermetabolism) and an activity factor of between 1.2 and 
1.3 (depending on the mobility of the patient and the intensity of physical therapy) can be used to 
determine energy requirements. Another guideline of 114-135% of the dietary reference intake 
(DRI) for healthy persons can be used during periods of active RA. If the patient is immobile, the 
Harris Benedict equation can be used without an activity factor and energy intake should be 
adjusted for weight changes that may occur over time. If the dietary intake is inadequate, a 
supplement should be taken to ensure that the energy requirements are met.45,94 
 
1.3.2 Protein Requirements 
Well nourished individuals with RA do not have increased protein requirements and the DRI for 
age and sex will provide sufficient protein in these patients. Patients with a poor nutritional status 
or those who are in the inflammatory phase have protein requirements of between 1.5 and 2 g 
protein/kg/day.45,94 In a study conducted by Marcora et al95, the effect of amino acid mixtures 
administered to RA patients (as part of the protein requirements) significantly increased fat-free 
mass, total body protein, arm and leg lean mass, and some measures of physical function.95 
 
1.3.3 Fat Requirements 
A low intake of fats aggravates RA because the resulting low levels of vitamin A and vitamin E 
stimulates lipid peroxidation and eicosanoid production.94 An intake of 30% of total energy 
requirements is therefore recommended. It is also recommended that the types of fats consumed 
are changed (e.g. replacing omega 6 FA with omega 3 FA) rather than eliminating fat from the 
diet.45,94 
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1.3.4 Micronutrient Requirements 
It has been said that patients with RA may have increased requirements for folic acid, vitamin B6 
vitamin E, vitamin D, zinc and antioxidants but no specific recommendations on exact quantities 
exist. Patients with RA may also have increased requirements of calcium and vitamin D.45,94,96 Little 
is known about the micronutrient doses needed to induce immunomodulation in RA and in the 
absence of clear guidelines, it is therefore advisable to reach at least the micronutrient intake of the 
DRI guidelines.85,94 
 
1.4 DIETARY RECOMMENDATIONS FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS 
Patients with RA should follow an individualized, healthy, balanced diet. It is important to avoid 
being overweight as this puts extra stress on the joints.45 Patients with RA should eat oily fish (e.g. 
mackerel, tuna, pilchards and salmon) three times a week or take omega 3 FA supplements.45 
Foods that tend to worsen the disease for that individual (e.g. dairy products, eggs, red meat, 
cereals, alcohol and chocolate) should be excluded.45 Sunflower oil used in cooking or salad 
dressings should be replaced with olive oil for the benefits of oleic acid. Foods containing high 
vitamin E content such as cereals, avocados, nuts, fruit and vegetables are recommended. 
Supplementation of vitamin B6, vitamin B12 and folate may be beneficial in patients with high 
homocysteine levels.46 Low doses of folate supplementation may have a supportive effect in 
patients using MTX however; vitamin B12 levels must be adequate to prevent deficiency of vitamin 
B12 due to nutrient-nutrient interactions.46 It is also recommended that adequate iron, calcium and 
vitamin D status is achieved from dietary intake or supplementation if necessary, especially in 
patients using prednisone.46 Foods rich in β-carotene such as carrots and sweet potatoes and 
foods rich in vitamin C such as broccoli, oranges and guavas are also recommended. Foods rich in 
selenium such as whole grains, cereals and eggs should also be eaten.45 Other recommendations 
which may be useful is to eat in a relaxed environment and to modify the kitchen layout of the 
patients home and use adapted cutlery to help with improving the ability of patients with RA to 
maintain adequate nutritional status.45,46 
 
In general, the diet recommended for arthritis is similar to that of good health with special emphasis 
on cardiovascular risk prevention (Table 1.3). These recommendations are according to the 
RACGP and include:45,70 
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Table 1.3. Dietary recommendations for RA70 
Dietary recommendations for RA 
1. Eat plenty of fruit, vegetables and wholegrain cereal foods 
2. Eat foods rich in fish oil (omega-3) 
3. Eat a diet low in saturated fat 
4. Maintain a healthy body weight 
5. Limit alcohol intake 
6. Eat only a moderate amount of sugar and foods containing sugars 
7. Choose low salt foods and use salt sparingly 
 
 
1.4.1 Dietary Recommendations for the Management of Cardiovascular Disease and 
Osteoporosis 
 
Due to the increased risk for CVD and osteoporosis, preventative lifestyle and dietary measures 
should be encouraged.18 Modifiable CVD risk factors such as dyslipidaemia and weight control 
should be addressed with dietary and lifestyle measures and serum carotenoid levels have been 
shown to increase with inclusion of fruit and vegetables in the diet.18,70 RA patients who present 
with osteoporosis as discussed earlier should meet the dietary recommendations for calcium intake 
from dietary sources where possible and calcium and vitamin D supplementation in older patients, 
particularly if housebound and/or in those with a poor dietary intake can be considered.18 
 
1.4.2 Omega 3 Fatty Acids and Exercise in Cardiovascular Disease and Osteoporosis 
The benefit of omega 3 FA and exercise is that it decreases the risk for CVD and osteoporosis and 
counteracts the complications associated with the natural course of RA and the effects associated 
with corticosteroids as discussed earlier.15 
 
Omega 3 fatty acids act to prevent heart disease in a number of ways including: prevent 
arrhythmias (ventricular tachycardia and fibrillation); are prostaglandin and leukotriene precursors;  
have anti-inflammatory properties; inhibit synthesis of cytokines and mitogens; stimulate 
endothelial-derived nitric oxide; are anti-thrombotic; have hypolipidaemic properties with effects on 
triacylglycerols and very low-density lipoprotein (VLDL); and inhibit atherosclerosis.97 Research 
has shown that omega 3 supplementation (0.045 to 5.9 g/day) lowers triglyceride levels while 
improving the HDL cholesterol and the ratio of total cholesterol to high-density-lipoprotein 
cholesterol with no changes in LDL cholesterol. Omega 3 PUFA supplementation has therefore 
shown the advanced beneficial effects of treatment of the disease and its potential 
complications.98,99 
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The anti-inflammatory properties of omega 3 FA have also shown to have potential positive effects 
on osteoporosis and general bone health. The basis of this involves the inverse relationship of 
omega 3 PUFA and pro-inflammatory eicosanoids such as cytokines that stimulate bone resorption 
by activating osteoclasts, cells that demineralise and degrade bone during bone remodeling.92 
Furthermore, Omega 3 FA supplementation (2.7 to 4.0 g/day) has been shown to decrease the 
need for high doses of corticosteroids in the treatment of RA.81 It would therefore be beneficial to 
note that supplementation with omega 3 FA may decrease required dosage of corticosteroids and 
therefore decrease risks of developing osteoporosis as a complication of RA. 
 
Exercise has been shown to decrease the risk of cardiovascular disease by reducing the risk of 
atherosclerosis due to decreased triglyceride (TG) and circulating atherogenic lipoproteins in the 
blood while also increasing the levels of beneficial HDL cholesterol.100 A study by Ho et al100 of 30 
minutes of different types of exercise showed that in overweight and obese men and women, 
aerobic exercise lowered postprandial serum triacylglycerol concentrations (the first blood sample 
was taken in the fasting condition and then at 1, 2, 3, 4, 5, 6 and 8 h after the meal) compared with 
the control, resistance exercise or combined trial groups and resistance exercise improved 
indicators of insulin sensitivity compared with aerobic exercise group.100 A reduction in postprandial 
serum triacylglycerol concentrations, postprandial insulin concentrations and insulin resistance was 
also shown in obese men with fasting hypertriglyceridaemia and insulin resistance after low to 
moderate intensity aerobic exercise performed for one hour.101 
 
1.5 IMPACT OF RHEUMATOID ARTHRITIS ON NUTRITIONAL STATUS 
It has been shown that persons with RA tend to have a poor nutritional status, reduced energy 
intake from carbohydrates, a high intake of saturated FA and a poor micronutrient intake.46,84 The 
prevalence of malnutrition (rheumatoid cachexia and wasting) in RA varies widely due to different 
methods of determining malnutrition and various populations and has been reported to be between 
26 and 71%.102 The chronic inflammation seen in RA increases metabolic rate and nutritional 
requirements and can therefore lead to impaired nutritional status.103 A few other factors which 
could also contribute to a poor nutritional status are an inadequate dietary intake and drug-nutrient 
interactions.46,102,104 Decreased dietary intake attributes to the poor nutritional status of many 
patients with RA.  Nausea and reduced appetite, due to medication, as well as fatigue and pain 
with difficulty in chewing and swallowing caused by temporo-mandibular involvement, are 
contributory factors.45 Dry mouth, dental caries and infection of gums causes a change in taste 
sensation. Another important aspect is that patients with RA who are experiencing pain may have 
a limited ability to go shopping for food, or prepare healthy, well balanced meals. These patients 
often resort to eating low energy, nutritionally poor snacks which are quick and convenient.45 
Another factor is that drug-nutrient interactions may result in increased nutrient requirements, 
decreased absorption of nutrients and gastro-intestinal discomfort.46 
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1.5.1 Body Composition 
Changes in body composition occur in patients with RA where progressive erosion of fat-free mass 
(FFM) occurs.  Assessment of body composition can demonstrate this in obese as well as normal 
and undernourished RA patients. Loss of FFM is very important because in starvation, critical 
illness, and normal aging, a loss of greater than 40% of baseline FFM has been shown to be 
associated with death.  As little as a 5% loss of FFM has caused changes in morbidity, including 
loss of muscle strength, altered energy metabolism, and increased susceptibility to infections. The 
average loss of FFM among patients with RA is between 13% and 15%, which is roughly one third 
of the maximum survivable loss of FFM.104 
 
Book et al105 found that lean mass of arms and legs (LMAL) was low in RA patients for both women 
and men (p=0.007 and <0.001, respectively). Body mass index (BMI) (p=0.012), body fat mass 
(BFM) (p=0.014) and truncal fat distribution (TFD) (p<0.001) was higher than expected in RA 
women. With adjustment for age and current smoking, disease duration was independently 
associated with low LMAL in women (p=0.021). High TFD was associated with a history of 
diabetes or CVD in men with RA (p=0.005). The authors concluded that low LMAL, high BFM and 
high TFD are present in early RA patients.105 Resmeni et al106 found that RA patients had a greater 
waist-hip ratio (WHR) (p<0.01), less lean body mass (LBM) (p<0.01), and lumbar bone mineral 
density (BMD) (p<0.01) than controls.106 Giles et al107 found that the HAQ score was strongly 
correlated with levels of physical and sedentary activity and body composition, with increasing fat 
and decreasing lean mass associated with higher HAQ scores. The mean HAQ score was 0.52 
units higher for subjects in the highest versus the lowest quartile of appendicular fat mass 
(p<0.001), and 0.81 units higher for subjects in the lowest versus the highest quartile of 
appendicular lean mass (p<0.001).  Body composition, particularly the amount of fat and lean 
mass located in the arms and legs, is therefore strongly associated with disability in RA patients.107  
 
1.5.2 Rheumatoid Cachexia and Cachetic Obesity 
The term rheumatoid cachexia is used to describe the loss of body cell mass, mainly in skeletal 
muscle, that occurs in nearly two-thirds of all patients with RA.108 It differs from acquired immune 
deficiency syndrome (AIDS), cancer and cardiac cachexia in that it does not necessarily manifest 
in weight loss.102,108 Rheumatoid cachexia generally occurs without a loss of fat mass and body 
weight. In actual fact, body cell mass is often lost in the presence of increased fat mass and stable 
body weight. This predisposes to a condition that has been termed ‘rheumatoid cachectic 
obesity’.108 Rheumatoid cachexia leads to muscle weakness and a loss of functional capacity, and 
is said to accelerate morbidity and mortality in RA.108 The exact mechanism for rheumatoid 
cachexia is not known, but it is accompanied by increased resting energy expenditure, increased 
whole-body protein catabolism, and excess production of the inflammatory cytokines, TNF-α and 
IL-1.24 TNF-α is believed to be the central mediator of muscle wasting in RA, and is known to act 
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together with IL-1 and influence muscle protein turnover. The exact mechanism by which this 
happens has yet to be revealed, but may involve other cytokines, sarco-active (muscle active) 
transcription factors and hormones.108 In addition to excess inflammatory cytokine production, 
decreased peripheral insulin action and low physical activity are believed to play important roles in 
the general development of rheumatoid cachexia and contributes towards muscle wasting. Low 
physical activity also leads to fat gain and is believed to precipitate a negative reinforcing cycle of 
muscle loss, reduced physical function, and fat gain in RA.108 No consensus exists for the exact 
cut-off values for rheumatoid cachexia but has been defined as fat-free mass index (FFMI) below 
the 10th percentile and FMI above the 25th percentile or FFMI below the 25th percentile and FMI 
above the 50th percentile of a reference population of age and sex-matched Europeans.( 2,982 
men and 2,647 women from Switzerland).109,73 
 
There is currently no standard treatment for rheumatoid cachexia. However, physical exercise is 
believed to be the most important and clinically relevant countermeasure against this condition. In 
general, a combination of skeletal muscle strength training and aerobic exercise is recommended, 
but must be prescribed with the patient’s disease status, overall health, and safety in mind.55,108 
 
In a study by Elkan et al73 on RA patients, the simultaneous decrease in fat free mass and increase 
in fat mass was shown in 18% of the women and 21% of the men and it was shown that 57% of 
the women and 89% of the men presented with central obesity.73 In another study done by Elkan et 
al109, the mean BMI for women and men was 25.0 and 27.0 kg/m2, respectively. Central obesity 
was found in 57% of the women (waist circumference >80 cm) and in 89% of the men (waist 
circumference >94 cm). In this study, 18% of the women and 26% of the men had rheumatoid 
cachexia. This condition was also associated with high levels of LDL cholesterol, low levels of 
atheroprotective anti-PC and a high frequency of hypertension, which is of interest in the context of 
CVD in RA. The increase in FM seen in RA patients, especially central obesity may also add to the 
CVD morbidity. Data on waist circumference in RA patients in other studies are sparse.109 In 
another study by Elkan et al102, BMI for women and men were 24.4 and 26.9 kg/m2 respectively 
and according to a BMI of < 18.5 kg/m2, only 12% of the women and none of the men were 
malnourished. FFMI however indicated that 52% of the women and 30% of the men were in fact 
malnourished according to their body composition.102 Because rheumatoid cachexia is common in 
patients with RA, and BMI alone cannot detect it, it is important to evaluate body composition and 
ensure that the fat free mass as well as the fat mass is determined in order to detect rheumatoid 
cachexia. 73,109 
 
In the South African context, a study done by Kalla et al110 in 1992 showed that young RA patients 
did not differ in nutritional status compared with healthy matched controls.110 Mody et al111 in 1989 
found that 20.5% of RA patients had a reduction of one or more anthropometric measurements 
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[triceps skinfold (TSF), upper arm muscle circumference (UAMC) and/or percentage ideal body 
weight (IBW)] and obesity was seen in 10.5% of the RA patients.111 Both these studies were done 
many years ago and changes in healthcare and medication in RA patients as well as dietary intake 
and patterns (i.e. the nutrition transition) and nutritional status in the general population may have 
occurred and data on nutritional status, specifically regarding waist circumference, fat free mass 
and fat mass, is warranted.  
 
1.5.3 Body Composition Measurement Techniques 
Anthropometry is the measurement of body size, weight, proportions and skinfolds and can be 
used to evaluate nutritional status and is considered as a method of choice for estimating body 
composition and is comparable to hydrostatic weighing. The advantages of this method are that 
the equipment is relatively inexpensive and requires little space. Dual X-Ray Absorptiometry 
(DEXA) scans are primarily used to evaluate bone mineral density and can also be used to 
measure total body composition and fat content with a high degree of accuracy comparable to 
hydrostatic weighing. Advantages of this method are that it is easy to perform with no discomfort 
for the participant. It is however considerably more expensive than anthropometric 
measurements.112 Another method which can be used to calculate body composition is bioelectrical 
impedance. The problem with this method however is that it assumes that the subject is normally 
hydrated. Dehydration can result in the overestimation of fat mass and subjects therefore need to 
be instructed prior to their appointment to prevent dehydration by drinking plenty of water, 
refraining from the consumption of any alcohol or caffeine the day before testing and avoiding 
heavy exercise for 12 hours before the test.112  
 
1.5.4 Nutritional Status of South Africans 
The nutritional status of South Africans is outlined in Table 1.4. In South Africa, the 1998 South 
African Demographic Health Survey (SADHS)113 showed that the mean BMI for women was 27 
kg/m2 which is classified as being overweight (BMI of 25-29.9 kg/m2) and 23.4 kg/m2 for men which 
is classified as normal (BMI of 18.5-25 kg/m2). These statistics proved to be very similar in 2003 
SADHS114 with a BMI of 27 kg/m2 for women and 23.3 kg/m2 for men.  In 1998, the obesity (BMI > 
30 kg/m2) statistics stood at 30.1% for women and 9.3% for men whereas in 2003 it showed 27.4% 
in women and 8.8% in men.113,114 The waist circumference measurement is an indicator of central 
obesity and according to the World Health Organization, a waist circumference of higher than 
80cm in women and 94cm in men indicated an increased risk of metabolic complications and 88cm 
in women and 102cm in men indicates a substantially increased risk of metabolic complications.115 
In 1998 the SADHS showed that women had a mean waist circumference of 85.8cm (indicating an 
increased risk) and 82.1cm for men (indicating no increased risk). In 2003, the figures had 
decreased slightly to 82.7cm in women (still indicating an increased risk) and decreased to 78.2cm 
in men.113,114 
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Obesity is found to be common among South African women (refer to Table 1.5). The obesity 
prevalence is highest in the African population, specifically the urban African population. The 
highest prevalence of obesity of 59% has been observed among Black women aged 45-54 years in 
the BRISK study.116 The Black women aged 15-64 years in the BRISK study also had the highest 
mean obesity prevalence of 34.4%. The prevalences are much lower for men.116 
It is therefore apparent that South Africa has a very high obesity prevalence, especially among 
women. It is therefore plausible to assume that a high prevalence of obesity could be found in the 
South African RA population. 
Table 1.4. Anthropometrical status of South African individuals 
Indicator Women Men Study 
Mean BMI (kg/m2) 27  23.4 1998 SADHS113 
27 23.3  2003 SADHS114 
Percentage of overweight (BMI of 
25-29.9 kg/m2) 
26.1%  19.8%  1998 SADHS113 
27.5%  21%  2003 SADHS114 
Percentage of obesity (BMI > 30 
kg/m2) 
30.1%  9.3%  1998 SADHS113 
27.4%  8.8%  2003 SADHS114 
Waist circumference (Mean values in 
cm) 
85.8cm  82.1cm  1998 SADHS113 
82.7cm  78.2cm  2003 SADHS114 
BMI= Body mass index / SADHS= South African Demographic and Health Survey. 
 
Table 1.5. Obesity statistics of South African individuals 
 Obesity statistic Study 
WOMEN 
  
African women aged 15 years and above 28.5%  2003 SADHS114 
African urban women aged 15 years and 
above 
33.8%  2003 SADHS114 
Coloured women aged 15 years and above 26.5%  2003 SADHS114 
White women aged 15 years and above 13.7%  2003 SADHS114 
Indian women aged 15 years and above 24.8%  2003 SADHS114 
Black women aged 15-64 years 34.4 BRISK study116 
Black women aged 45-54 years 59% BRISK study116 
Coloured women aged 45-54 years 42.6% CRISIC study117 
Indian women aged 45-54 years 40% Indian Study118 
White women aged 45-54 years 23.8%  CORIS study119 
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 Obesity statistic Study 
MEN 
  
Black men aged 15 to 64 years 7.9% BRISK study116 
Black men aged 55 to 64 years 28.6 % BRISK study116 
White men aged 15-64 years  14.7 % CORIS study119 
SADHS= South African Demographic and Health Survey 
 
1.6 MOTIVATION FOR STUDY 
RA is a potentially debilitating disease with high healthcare costs to both the private and public 
health sectors. There are no recent studies in SA investigating the nutritional status and/or body 
composition of patients suffering from RA. It is evident from studying the literature that there are a 
number of areas of concern in terms of health and nutrition in RA patients and in South Africa too, 
such as the high obesity statistics. The study aimed to establish what RA patients are practicing 
and their perceptions regarding the effect of diet, nutritional supplements, medication and CAM on 
their symptoms as well as determining their body composition and the possible presence of 
rheumatoid cachexia. It is worthwhile investigating this area if their symptoms could be improved 
by diet or nutritional supplementation and by paying attention to the anthropometrical status 
especially if obesity and rheumatoid cachexia are found in the SA RA population. This will certainly 
be valuable information for healthcare workers, particularly rheumatologists and dietitians, in South 
Africa in benefiting and optimising the healthcare and support of RA patients. 
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CHAPTER 2: METHODOLOGY 
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2.1 AIM 
The aim of the study was to determine the body composition of RA patients in the private and 
public health sector in the Cape Metropole as well as their perceptions and practices regarding the 
use of diet, nutritional supplements, medication, complementary and alternative medicines/ 
therapies and exercise in the treatment of the disease. 
 
2.2 OBJECTIVES 
1. To determine the body composition of RA patients by using weight, height, bicep-, tricep-, 
supra-ileac and subscapular-skinfolds, waist circumference and the appropriate prediction 
equations. 
2. To determine the perceptions and practices of RA patients regarding the use and 
adaptation of diets and nutritional supplements in the treatment of RA. 
3. To determine the perceptions and practices of RA patients regarding the use of medication 
and other forms of complementary and alternative medicines/therapies in the treatment of 
RA. 
4. To determine the perceptions and practices of RA patients regarding the use of exercise in 
the treatment of RA. 
5. To compare the nutritional status, diet and medication facets of private and public health 
sector patient groups. 
 
2.3 NULL HYPOTHESIS (H0) 
There are no differences in terms of body composition, diet and medication use between the 
private and public sector participants. 
 
2.4 STUDY METHODOLOGY 
2.4.1 Study Type 
The study design was a descriptive, cross-sectional study with an analytical component in the 
quantitative domain. The study techniques included an interviewer-administered questionnaire and 
anthropometrical measurements. 
 
2.4.2 Study Population  
The study population consisted of adult (18 years or older) RA patients in the Cape Metropole from 
the private as well as the public sector.  
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2.4.3 Sample Selection and Size 
The sampling frame consisted of all RA patients attending the public sector RA clinics at Tygerberg 
Hospital (TBH) and Groote Schuur Hospital (GSH) in order to reach the lower socio-economic 
groups. RA patients utilising private medical care were also recruited in order to reach the higher 
socio-economic groups. Purposive sampling was used since the study population is small. 
 
Approval to conduct the research study in the above mentioned tertiary hospitals was sought from 
the Western Cape Provincial Health Research Committee. The Rheumatology clinics at TBH and 
GSH were contacted thereafter for logistical arrangements. Permission to conduct the study in the 
clinics was obtained from the Medical Superintendent and the respective heads of the clinics also 
granted their permission. All private practicing rheumatologists in the Cape Metropole were 
contacted to request permission for their patients to be approached to be included in the study 
population. 
 
The total required population sample size was calculated in consultation with a statistician. With a 
confidence interval of 95% and a precision error of 0.6, a total of 267 RA patients were required. In 
order to compare the private and public sector groups, 67 RA patients were required in the private 
sector group according to a 1-way ANOVA power analysis with an effect size of 0.4. 
 
2.4.4 Inclusion Criteria 
All English, Afrikaans and Xhosa speaking RA patients living in the Cape Metropole area who were 
18 years and older were eligible for inclusion. 
 
2.4.5 Exclusion Criteria 
RA patients younger than 18 years, those who did not give consent to partake in the study or those 
who participated in the pilot study were excluded. 
 
2.5 METHODS OF DATA COLLECTION 
Data collection was conducted by the investigator and took place from 11 January until the 25 
February 2011 from GSH in Cape Town, TBH in Bellville, and three private practices that agreed to 
partake in the study across the Cape Metropolitan area including Stellenbosch, Pinelands and 
Panorama. An interviewer-administered questionnaire (Addendum A and B) followed by the 
measurement of weight, height and waist circumference in all patients and skinfold thickness 
measurements in patients with a BMI of <30 was conducted. Information was also gathered from 
the medical records. 
 
The TBH clinic was attended on Monday and Tuesday mornings between 09h00 and 13h00. The 
RA clinic at GSH was attended on Friday mornings between 08h00 and 13h00. The private 
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patients were seen according to a schedule on the remaining open time slots. The private patients 
were approached at the rooms of the private practicing rheumatologists and invited to participate in 
the study and those who agreed were then seen after their doctor’s appointment. In order to 
ensure privacy, a vacant room with sufficient space to conduct the measurements was utilized.  
 
The questionnaires were administered and filled out by the investigator in a face-to-face manner 
for both private and public participants in a private room to ensure that the participant was 
comfortable and confidentiality was kept. The questionnaire was structured as to limit potential 
detection/observer bias and the investigator was well trained and followed standardized interviewer 
and measurement procedures. The questionnaire was compiled by the investigators and questions 
included were based on the latest literature and according to the objectives so that the answers 
would provide the relevant data to be able to determine the objectives. The questionnaire included 
questions on personal information (7 questions), the practices regarding the use of special diets, 
nutritional supplements and other forms of CAM (6 questions), perceptions regarding foods which 
improve or worsen their symptoms (5 questions), known/history of food allergies (1 question) and 
questions on the use of medication - both prescribed and self-medication (8 questions) and 
exercise (6 questions). A consent form (Addendum C and D) stated the details about what the 
study was about, how the results would be used, how long it would take to complete as well as the 
details regarding obtaining consent to partake in the study. The consent form was signed for each 
participant before data collection commenced in order for them to partake in the study. The 
questionnaire and consent forms were translated into Afrikaans and Xhosa with the help of a 
translator. Consent on the part of the participant included consent for the questionnaire, 
measurements taken as well as access to their medical records in order to obtain any relevant 
information regarding existing co-morbidities which could affect their nutritional status and what 
medication had been prescribed (See Table 2.1). No follow up was required.  
 
Table 2.1. Information gathered from medical records of each patient 
Information Reason/ Relevance 
Comorbidities/ Medical 
history of note 
Possible influence on nutritional status or the type of 
medication used. 
Prescribed Medication  Quantitative data and for statistical analysis and 
comparison between the public and private sector. 
 
Anthropometrical measurements including weight, height, and waist circumference were measured 
according to the Nutritional assessment method112 and the bicep-, tricep-, supra-ileac and 
subscapular-skinfolds were measured according to International Standards for Anthropometric 
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Assessment by the International Society for the Advancement of Kinanthropometry (ISAK).120 The 
anthropometrical measurements were measured as outlined in Table 2.2 below.  
Table 2.2. Anthropometrical measurements taken (112,120) 
Measurement & 
equipment Details of how it was taken
 
Standardization and reliability 
techniques 
Weight 
 
Electronic scale  
(AEG Electrolux) 
• Scale placed on a flat, hard surface 
• Measure without shoes and with minimum clothing   
• Participant stands in the middle of the platform without support 
and weight distributed evenly on both feet 
• Measurement taken correctly to the nearest 0.1 kg 
• Zero calibration before each 
weight measure 
Height 
 
Stadiometer 
(Leceister 214 
Portable Stadiometer) 
• Nothing covering the head 
• Feet together and flat on the floor 
• Legs straight and knees together 
• Arms relaxed at the sides 
• Heels, buttocks, and upper part of the back touching the 
stadiometer 
• Frankfort plane forms a 90 degree angle with the baseboard  
• Measurement taken at maximum inspiration 
• Measuring stick is brought down until it touches the head 
• Measurement taken correctly to the nearest 0.1cm 
• Standardised equipment 
used  
Skinfolds (General) 
 
Harpenden calliper 
• Measurements taken on the right hand side 
• Locate the skinfold site by marking the correct anatomical 
landmark once it is identified 
• Skin and subcutaneous fat layer are grasped and picked up 
on the skinfold site by the thumb and index finger of the left 
hand  
• Care must be taken not to pick up the underlying muscle 
tissue in the grasp 
• Calliper held in right hand, perpendicular to the long axis of 
the skinfold and with the dial facing up 
• Blades of the calliper are applied 1cm away from the edge of 
the thumb and index finger 
• Calliper blades to be placed in the middle of the base and top 
of the skinfold 
• Skinfold is held while the measurement is taken 
• Take measurement 2 seconds after releasing the calliper 
blades fully 
• Measurement taken correctly to the nearest 1 millimetre  
• All skinfolds should be measured in succession and repeated 
three times (in other words, a complete data set of the whole 
proforma is taken and then repeated a second and then third 
time)  
• Zero calibration before each 
measurement 
• Average of three 
measurements taken 
• Measurements should not 
differ by more than 1mm 
Mid-acromiale-radiale 
(Midpoint of the arm) 
• Midpoint of the straight line joining the Acromiale (superior 
aspect of the most lateral part of the acromion border) and 
the Radiale (point at the proximal and lateral border of the 
head of the radius) 
 
Tricep Skinfold Site • Point on the posterior surface of the arm in the mid-line at the 
level of the marked Mid-acromiale-radiale 
• Subject stands relaxed with arms hanging by the side in the 
mid-prone position 
• Located by projecting the Mid-acromiale-radiale site 
perpendicularly to the long axis of the arm around to the back 
of the arm and intersecting the projected line with a vertical 
line in the middle of the arm when viewed from behind 
 
Tricep Skinfold 
Measurement 
• Measurement is taken parallel to the long axis of the arm at 
the Triceps skinfold site 
• Measurement taken correctly to the nearest 1 mm 
 
Bicep Skinfold Site • Point on the anterior surface of the arm in the midline at the 
level of the Mid-acromiale-radiale 
• Subject stands relaxed with arms hanging by the side  
• Located by projecting the Mid-acromiale-radiale site 
perpendicularly to the long axis of the arm around to the front 
of the arm and intersecting the projected line with a vertical 
line in the middle of the arm when viewed from the front 
 
BicepSkinfold • Measurement is taken parallel to the long axis of the arm at 
the Biceps skinfold site 
• Measurement taken correctly to the nearest 1 mm 
 
 
Subscapular Skinfold • 2cm along a line running laterally and obliquely downward  
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Measurement & 
equipment Details of how it was taken
 
Standardization and reliability 
techniques 
Site from the Subscapulare (undermost tip of the inferior angle of 
the scapula) at a 45 degree angle 
• Subject stands relaxed with arms hanging by the side  
Subscapular Skinfold • Subject stands relaxed with arms hanging by the side  
• Taken with the fold running obliquely downwards at the 
Subscapular skinfold site as determined by the natural fold 
lines of the skin 
• Measurement taken correctly to the nearest 1 mm 
 
Iliac Crest Skinfold Site 
(Supra-iliac) 
• Site at the centre of the skinfold raised immediately above the 
Iliocristale (the point on the iliac crest where a line drawn from 
the mid-axilla on the longitudinal axis of the body meet the 
ilium) 
• Subject stands relaxed with the left arm hanging by the side 
and the right arm folded across the chest 
• Skinfold is raised superior to the Iliocristale by placing the left 
thumb tip on the Iliocristale and raise the skinfold and mark its 
centre with a cross 
• Skinfold runs slightly downwards anteriorly as determined by 
the natural fold of the skin 
• Measurement taken correctly to the nearest 1 mm 
 
Supra-iliac Skinfold • Subject stands relaxed with the left arm hanging by the side 
and the right arm folded across the chest 
• Taken near horizontally at the Iliac Crest skinfold site 
• Skinfold runs slightly downwards anteriorly as determined by 
the natural fold of the skin 
• Measurement taken correctly to the nearest 1 mm 
 
Waist circumference 
 
Tape measure - 
material 
(Seca201 Girth 
Measuring Tape) 
• Measurement is taken over minimal clothes 
• Measurement is taken at the narrowest point of the abdomen 
between the lower costal (10th rib) border and the top of the 
Iliac crest perpendicular to the long axis of the trunk 
• Subject stands relaxed with arms folded across the thorax 
• Measurer stands in front of the person 
• Measuring tape does not cut into the skin  
• Measurement is taken after exhalation 
• Standardised equipment 
used. 
 
The investigator received ISAK level 1 accreditation* and was well trained and standardized in 
taking the measurements correctly by a trained and experienced ISAK accredited course instructor 
from Stellenbosch University during a three day workshop using training material and focusing on 
the practical aspects of taking the various measurements. This ensured that the investigator 
performed the measurements in a standardised manner and contributed to the reliability of the 
measurements. Reliability of the measurements was ensured by repeating the measurements 
three times and taking the average value where appropriate. This method (from Lee and 
Nieman112) is a slight deviation from the ISAK method as the researcher was not able to carry a 
laptop around to compute the measurements due to safety reasons. The allowed error rate in ISAK 
(10%) is however very similar to the method used in this study (<1mm difference). Skinfold 
measurements were not taken for individuals with a BMI of >30kg/m2  due to the reduced accuracy 
of the measurements taken in these individuals and the resulting measurement errors which may 
influence the prediction accuracy of body density. Also, the equations used to calculate body 
density show a lack of accuracy in predicting body composition in overweight populations.98,121,132 
 
                                                 
*
 ISAK level 1 accreditation: The International Society for the Advancement of Kinanthropometry (ISAK) has developed international 
standards for anthropometric assessment and an international anthropometry accreditation scheme (IAAS). Level 1 is designed for the 
majority of ISAK-accredited anthropometrists who require the measurement of height, weight, circumferences and skinfolds. 
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The pre-coded questionnaire and data collection sheet was sent to the statistician before pilot 
testing was conducted in order to ensure that the data obtained from the questionnaire would be 
useful and meaningful. 
 
The questionnaire was tested for content validity by experts in the field, namely, Prof. Reuter 
(private practicing rheumatologist) and Dr Whitelaw (Head of Rheumatology: TBH). Face validity 
was tested by a sub-group of the population in a pilot test. Consensual validity was also reached 
whereby all the involved investigators, who are experts in their field, agreed on the validity of the 
questionnaire and the methodology aspects of the research study. Two participants each from 
TBH, GSH and the largest private practice was used for the pilot study. The pilot study took place 
during December 2010. Convenience sampling was used to select individuals for the pilot study. 
Small changes emanating from the pilot study were made to the questionnaire, these included 
removing ambiguous/repetitive questions and better phrasing some of the questions. 
 
2.6 ANALYSIS OF DATA 
The data was analyzed with the assistance of a statistician, Prof. Daan Nel, appointed by 
Stellenbosch University. MS Excel was used to capture the data and STATISTICA version 10 
[StatSoft Inc. (2010) STATISTICA (data analysis software system) www.statsoft.com] was used to 
analyze the data. The data was captured by the researcher and a research assistant. 
 
Summary statistics were used to describe the variables measured. Distribution of variables was 
presented with histograms and frequency tables. Means were used as the measures of central 
location for ordinal and continuous responses and standard deviations as indicators of spread. The 
relation between two nominal variables was investigated with contingency tables and maximum 
likelihood ratio chi-square tests. A p-value of p< 0.05 represented statistical significance in 
hypothesis testing.  
 
The data was captured in a pre-coded data collection sheet and processed in order to obtain 
results. The anthropometrical data was used to calculate, interpret and classify/ categorise BMI, 
percentage body fat, waist circumference, fat mass index and fat-free mass index (Table 2.3). All 
skinfold measurements were interpreted using relevant reference standards, percentile 
distributions and indices (graphs and tables) referenced from appropriate sources.112,115,123,124 
Education was classified into primary school level (Grade R to Grade 7), Secondary school level 
(Grade 8 to Grade 12), Secondary school graduate (Grade 12 graduate) and Tertiary education 
level (Degree/ Diploma). Exercise was classified according to the World Health Organization 
Global Strategy on Diet, Physical Activity and Health.125 Since absolute FFM and FM are 
dependent of height, the fat free mass index (FFMI; kg/m2) and fat mass index (FMI; kg/m2) were 
calculated. Fat mass index (FMI) and fat-free mass index (FFMI) was classified according to age-
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matched and sex-matched data from a Swiss population of healthy adults (2986 men and 2649 
women).109,124 No consensus exists about the cut-off  levels for rheumatoid cachexia, we used the 
definition of FFMI below the 10th percentile together with FMI above the 25th percentile.109,73 A cut-
off value for low FFM was defined as FFMI below the 10th percentile and obesity according to FMI 
was defined as FMI above the 90th percentile, as defined by the reference population.109 
 
Table 2.3. Calculation and classification of anthropometrical data (112,115,123,124,125) 
Anthropometrical 
measurement 
Calculation thereof/ equation Interpretation and classification 
Body Mass Index (BMI)  
(kg/m2)115 
Weight(kg) / Height2(m) Undernutrition: 
Severe thinness 
Moderate thinness  
Mild thinness 
Normal:  
Overweight:  
Obese 
Obese Class 1:  
Obese Class 2:  
Obese Class 3:  
< 18.5 
<16.00 
16.00 - 16.9 
17.00 - 18.49 
18.5-24.9 
25-29.9 
>30 
30-34.9 
35-39.9 
≥ 40 
Waist Circumference 
(cm)115 
N/A * Increased risk: >94cm – Males 
                          >80cm – Females 
*Substantially increased risk: >102cm – Males 
                                             >88cm – Females 
Sum of skinfolds (mm) Ʃ) Summation of all four skinfold values  
Body Density (D) 
(Durnin and Womersley 
equation for calculating 
body density)112 
Males 
17-19 
20-29 
30-39 
40-49 
50+ 
Females 
17-19 
20-29 
30-39 
40-49 
50+ 
Equation: 
1.1620 - 0.0630 x (log Ʃ) 
1.1631 - 0.0632 x (log Ʃ) 
1.1422 - 0.0544 x (log Ʃ) 
1.1620 - 0.0700 x (log Ʃ) 
1.1715 - 0.0779 x (log Ʃ) 
 
1.1549 - 0.0678 x (log Ʃ) 
1.1599 - 0.0717 x (log Ʃ) 
1.1423 - 0.0632 x (log Ʃ) 
1.1333 - 0.0612 x (log Ʃ) 
1.1339 - 0.0645 x (log Ʃ) 
Percentage Body Fat 
(%BF) Categories 
(Siri equation for 
calculating percentage 
body fat)112 
(495 / D) - 450  
Unhealthy range 
(too low) 
Acceptable range 
(lower end)  
Acceptable range 
(upper end) 
Unhealthy                
(too high) 
Males 
≤ 5% 
 
6-15% 
 
16-24% 
 
≥25% 
Females 
≤ 8% 
 
9-23% 
 
24-31% 
 
≥ 32% 
Fat Mass (kg)112 Body Weight x %BF N/A 
Fat-free Mass (kg)112 Body Weight – Fat Mass N/A 
Fat Mass Index (FMI) 
(kg/m2) plus 
Categories124 
Fat Mass / Height2(m) See Reference 124 
Low FFMI: <10th percentile 
Fat-free Mass Index 
(FFMI) (kg/m2) plus 
Categories124 
Fat-free Mass / Height2(m) See Reference 124 
Obesity: FMI >90th percentile 
Exercise Categories125 N/A Low intensity: Yoga, Pilates, Stretching, etc. 
Moderate intensity: Walking, Running, 
Swimming, Cycling, etc. 
High intensity: Weights, etc. 
Low amount: <150 mins/week 
Moderate amount:150-300 mins/week 
High amount: >300 mins/week 
* Disease risk for metabolic complications 
BMI= Body Mass Index; D= Body Density; Ʃ=Sum of skinfolds; BF= Body fat; FFMI= Fat-free Mass Index; FMI= Fat Mass Index 
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2.7 ETHICS AND LEGAL ASPECTS 
The protocol and all the relevant addenda were submitted to the Health Research Ethics 
Committee of Stellenbosch University for ethics approval (Approval number: N10/09/292; 
Addendum E). Autonomy was upheld by means of a consent form (in English and Afrikaans; 
translator used for Xhosa participants) that the participants had to sign in order to partake in the 
study. The consent form explained that participation was voluntary and explained all aspects of 
exactly what the study entailed regarding the questionnaire, the information that was sourced from 
the medical records (see Table 2.1), the measurements that were taken and how the information 
will be used. The participants were assured that the information would remain private and 
confidential at all times. The consent form obtained consent to partake in the study, to answer the 
questionnaire, to be measured, to obtain medical records and to use the information in the results 
of the study. The questionnaire was administered in the participant’s preferred language. The 
investigator is fluent in writing, reading and speaking English and Afrikaans. In the case of a Xhosa 
speaking participant, a translator was used. The individuals’ confidentiality and privacy was 
ensured by using a private room for the measurements to ensure the participant was comfortable 
as well as through a coding system whereby each participant received a coded number known only 
to the investigator.  
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CHAPTER 3: RESULTS 
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3.1 DEMOGRAPHICS 
A total of 251 participants agreed to partake in the study of which 201 participants were from the 
public sector and 50 participants were from the private sector. Questionnaire data was obtained 
from all participants. Anthropometrical measurements were obtained for 246 participants of which 
weight and height only was obtained for 1 participant and weight, height and waist circumference 
was obtained for 245 of the participants while a full set of anthropometrical measurements with 
skinfold measurements could only be taken for 117 of participants due to the limitation of skinfolds 
in obese participants amongst other reasons. See Figure 3.1 for the reasons for missing data in 
some of the participants. 
 
Figure 3.1. Reasons for missing anthropometrical data 
 
The mean age of the participants was 54.7 years (±SD:13.6) and the mean onset of disease was 
at 43.9 years of age (±SD:13.4). The study population consisted of 209 females (83%) [public 
sector: n=165 (66%); private sector: n=44 (18%)] and 42 males (17%) [public sector: n=36 (14%); 
private sector: n=6 (2%)]. The majority of the population were Coloured South Africans (n=172; 
Stellenbosch University  http://scholar.sun.ac.za
 40 
 
68%) and the rest were Caucasians (n=50; 20%) and Blacks (n=29; 12%). The mean duration of 
disease was 11 years (±SD:10.4) (Table 3.1). 
 
Table 3.1. Participant demographics 
Participants Demographic Valid N Mean Minimum Maximum SD 
All 
participants 
Age (years) 251 54.7 18.0 83.0 13.6 
 Pre-disease age 
(years) 
251 43.9 11.0 80.0 13.4 
 Duration of disease 
(years) 
251 11.0 1.0 63.0 10.4 
Females Age (years) 209 55.1 18.0 83.0 13.7 
 Pre-disease age 
(years) 
209 44.2 11.0 80.0 13.6 
 Duration of disease 
(years) 
209 11.2 1.0 63.0 10.4 
Males Age (years) 42 52.3 19.0 78.0 13.3 
 Pre-disease age 
(years) 
42 42.4 16.0 75.0 12.2 
 Duration of disease 
(years) 
42 10.6 1.0 52.0 10.5 
Public 
Sector 
Age (years) 201 54.2 18.0 83.0 13.3 
 Pre-disease age 
(years) 
201 43.1 11.0 80.0 13.2 
 Duration of disease 
(years) 
201 11.4 1.0 63.0 10.6 
Private 
Sector 
Age (years) 50 56.4 21.0 82.0 14.9 
 Pre-disease age 
(years) 
50 47.1 19.0 78.0 13.4 
 Duration of disease 
(years) 
50 9.8 1.0 47.0 9.4 
N= Number of participants; SD= Standard Deviation. 
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3.2 PATIENT CHARACTERISTICS 
Eighty percent (n=202) of the study population also suffered from diagnosed or self-reported co-
morbidities and risk factors for heart disease (Figure 3.2), where 65.8% (n=133) of participants had 
hypertension and 49.0% (n=99) had speculated gastric side effects due to the RA medication. The 
prevalence of a combination of co-morbidities and risk factors for heart disease in this study 
population is shown in Table 3.2. A combination of hypertension with a high waist circumference, 
obesity and smoking was seen in 35% (n=87), 31% (n=78) and 29% (n=74) of participants 
respectively.  
 
Figure 3.2. Co-morbidities and risk factors present in study population (n=202) 
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Table 3.2. Combinations of the presence of co-morbidities and risk factors in the study 
population 
Combinations of co-morbidities in study population Number of 
participants 
% of study 
population 
Hypertension + Hypercholesterolaemia 34 14% 
Hypertension +  Diabetes Mellitus 24 10% 
Hypertension + Smoker 74 29% 
Hypertension +  Obesity 78 31% 
Hypertension + Substantially increased risk WC 87 35% 
Hypercholestrolaemia + Smoker 24 10% 
Hypercholestrolaemia +  Obesity 25 10% 
Hypercholestrolaemia +  Substantially increased risk WC 30 12% 
Smoker + Obesity 49 20% 
Smoker + Substantially increased risk WC 59 24% 
Hypertension + Hypercholestrolaemia + Obesity 24 10% 
Hypertension + Hypercholestrolaemia + Substantially increased 
risk WC 
27 11% 
Smoker + Obesity + Substantially increased risk WC 46 18% 
WC= Waist circumference. 
Six percent (n=16) of the study population reported having a diagnosed food allergy with seafood 
(n=8; 50.0%) and fish (n=6; 37.5%) stated as the most common offenders (Figure 3.3). Fifty four 
percent (n=135) of the population were smokers/previous smokers with a mean of 26.1 years of 
smoking (±SD:14.3). Twenty four percent (n=61) did not attend secondary/high school and seventy 
five percent (n=114) of the study population that started to attend secondary/high school did not 
graduate. The distribution of the level of education in this study population is shown in Figure 3.4.  
 
Figure 3.3. Description of types of food allergies present (n=16) 
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Figure 3.4. Distribution of education level (n=251) 
 
3.3 BODY COMPOSITION 
The values for the anthropometrical measurements are outlined in Table 3.3. The average weight 
for females was 76.3kg (±SD:17.7) and 77.2kg for males (±SD:19.9). Seventy one percent (n=176) 
indicated self-reported weight gain (n=129) or weight loss (n=47) since their diagnosis of RA. The 
mean body mass index (BMI) was 30.3 kg/m2 for females and 26.6 kg/m2 for males. Body mass 
index, waist circumference, percentage body fat, fat mass index and fat free mass index for each 
individual was classified as described in the methodology section according to the classifications 
for men and women.  
   
Table 3.3. Anthropometrical measurements of female and male participants 
Participants Anthropometrical 
Measurement 
Valid N Mean Min Max SD 
 
All participants 
BMI (kg/m2) 246 29.7 16.4 61.8 6.7 
Gained weight (kg) 129 11.6 2.0 40.0 7.4 
Lost weight (kg) 47 10.5 2.0 70.0 11.6 
Females Weight (kg) 204 76.3 36.8 141.1 17.7 
Height (m) 204 1.6 1.4 1.8 0.1 
BMI (kg/m2) 204 30.3 17.8 61.8 6.7 
WC (cm) 203 91.3 60.0 125.0 14.4 
TSF Average (mm) 86 19.7 6.0 37.9 6.1 
BSF Average (mm) 86 9.2 2.8 21.3 3.8 
SISF Average (mm) 86 16.4 3.8 35.3 7.3 
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Participants Anthropometrical 
Measurement 
Valid N Mean Min Max SD 
SSSF Average (mm) 86 19.1 5.4 44.5 9.7 
Sum of SF (mm) 86 64.3 25.3 130.2 23.1 
% Body fat 86 33.8 13.7 46.2 5.9 
Gained weight (kg) 115 11.6 2 40 7.2 
Lost weight (kg) 40 11.4 2 70 12.4 
Males Weight (kg) 42 77.2 45.2 138.3 19.9 
Height (m) 42 1.7 1.5 1.9 0.1 
BMI (kg/m2) 42 26.6 16.4 47.9 6.1 
WC (cm) 42 92.7 64.0 134.0 16.4 
TSF Average (mm) 31 9.3 4.0 17.4 3.6 
BSF Average (mm) 31 5.1 2.1 9.5 2.1 
SISF Average (mm) 31 13.4 3.4 32.3 6.8 
SSSF Average (mm) 31 14.0 6.2 32.8 7.6 
Sum of SF (mm) 31 41.8 16.0 90.6 18.1 
% Body fat 31 21.5 7.0 35.8 6.9 
Gained weight (kg) 14 10.8 2 30 8.9 
Lost weight (kg) 7 5.4 2 10 3.1 
BMI= Body Mass Index; WC= Waist Circumference; TSF= Triceps Skinfold; BSF= Biceps Skinfold; SISF= Supra-Ileac 
Skinfold; SSSF= Subscapular Skinfold; SF= Skinfold 
BMI was used to classify obesity (n=133; 45.9%), overweight (n=66; 26.8%), normal weight (n=63; 
25.6%) and underweight (n=4; 1.6%) (Figure 3.5). Half of the females were classified as obese 
(n=103; 50.5%) and only 22.1% (n=45) as normal (Figure 3.5) while the males were classified as 
23.8% (n=10) obese and 42.9% (n=18) as normal (Figure 3.5).  
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 All participants (n=246) Females (n=204) Males (n=42) 
Obese (n) 113 103 10 
Overweight (n) 66 54 12 
Normal (n) 63 45 18 
Underweight (n) 4 2 2 
n= number of participants 
Figure 3.5. Body mass index classifications of participants (n=246) 
 
Waist circumference measurement classifications in all participants showed a substantially 
increased risk for metabolic complications in 127 participants (51.8%) and an increased risk for 
metabolic complications in 52 participants (21.2%) (Figure 3.6). In the women, 115 participants 
(55%) showed a substantially increased risk for metabolic complications and 43 participants 
(20.6%) had an increased risk for metabolic complications (Figure 3.6). The majority of men on the 
other hand had normal waist circumference values [50% (n=21)] (Figure 3.6). 
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 All participants (n=245) Females (n=203) Males (n=42) 
Substantially  
increased risk (n) 127 115 12 
Increased risk (n) 52 43 9 
Normal (n) 66 45 21 
n= number of participants 
Figure 3.6. Waist circumference measurement classifications of participants (n=245) 
 
Body fat percentage classification was distributed as shown in Figure 3.7. Just over half of all the 
participants (n=65; 55.6%) had an unhealthy high body fat percentage. In the female group (Figure 
3.7), 64% (n=55) had an unhealthily high body fat percentage compared to the men with 32.3% 
(n=10) presenting with an unhealthily high body fat percentage (Figure 3.7). 
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 All participants (n=117) Females (n=86) Males (n=31) 
Unhealthy high (n) 65 55 10 
Average  
(Upper range) (n) 44 29 15 
Average  
(Lower range) (n) 8 2 6 
n= number of participants  
Figure 3.7. Body fat percentage classifications of participants (n=117) 
 
A statistically significant positive linear relationship existed between waist circumference and 
percentage body fat, further indicating the presence of central obesity in this study population 
(Figure 3.8). This relationship was significant for both males and females, with p<0.0001 for both 
analyses. 
Females and Males
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WC= Waist circumference. 
Figure 3.8. Scatter plot of waist circumference versus body fat percentage for females and 
males 
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Fat mass index and fat-free mass index classification was distributed as shown in Figures 3.9 to 
3.11 and Figures 3.12 to 3.14 respectively. Sixty five percent of all participants (n=76) had a FMI of 
higher than the 50th percentile with 68.6% (n=59) FMI of higher than the 50th percentile for the 
women and 54.8% (n=17) for the men. A FFMI of lower than the 25th percentile was shown in 
29.1% (n=34) of all participants, 24.4% (n=21) of women and in 41.9% (n=13) of men. 
 
P= Percentile; n= number of participants. 
Figure 3.9. Percentile distribution of fat mass index for all participants (n=117) 
 
P= Percentile; n= number of participants. 
Figure 3.10. Percentile distribution of fat mass index for women only (n=86) 
 
P= Percentile; n= number of participants. 
Figure 3.11. Percentile distribution of fat mass index for men only (n=31) 
Stellenbosch University  http://scholar.sun.ac.za
 49 
 
 
P= Percentile; n= number of participants. 
Figure 3.12. Percentile distribution of fat-free mass index for all participants (n=117) 
 
 
P= Percentile; n= number of participants. 
Figure 3.13. Percentile distribution of fat-free mass index for women only (n=86) 
 
 
P= Percentile; n= number of participants. 
Figure 3.14. Percentile distribution of fat-free mass index for men only (n=31) 
 
Of the 117 participants whose skinfold measurements could be taken, rheumatoid cachexia 
(determined as described in methodology) was seen in twelve participants (10.3%) and these 
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participants were classified as underweight (n=1; 1%), normal weight (n=8; 7%) or overweight 
(n=3; 3%) and not obese using the BMI classification. Low fat-free mass classification according to 
FFMI (FFMI <10th percentile) was seen in 24 participants (21%) and obesity according to FMI (FMI 
>90th percentile) was seen in 31 participants (27%). 
 
3.4 DIET, NUTRITIONAL SUPPLEMENTS, COMPLEMENTARY AND ALTERNATIVE 
MEDICINES AND THERAPIES 
Twenty nine percent of participants (n=73) believed that certain types of food could improve their 
symptoms of RA (Figure 3.15). Vegetables (n=56; 76.7%) and fruit (n=24; 32.9%) were mentioned 
most frequently (Figure 3.17). Sixty percent of participants (n=151) believed that certain foods 
worsened their symptoms of RA (Figure 3.16). Tomatoes (70%), spicy food (56%) and red meat 
(39%) were the most frequently mentioned offenders (Figure 3.18).  
 
Figure 3.15. Foods improve the Figure 3.16. Foods worsen the symptoms 
symptoms of RA  of RA 
 
Figure 3.17. Types of foods thought to improve their symptoms of RA (n=73) 
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Figure 3.18. Types of foods thought to worsen their symptoms of RA (n=151) 
 
Half of the participants (n=126) stated that they avoid certain foods which they believe worsen their 
symptoms and 19% (n=48) increase their intake of certain foods to improve their symptoms of RA. 
Of those participants that avoid certain foods, 41% percent (n=52) replace that type of food with a 
different source of the nutrients which are consequently excluded from their diet. Of those 
participants who believed foods can improve their symptoms of RA (n=73), Figure 3.19 illustrates 
the distribution of those who actively increase their intake of the type of food they believe improves 
their symptoms and those who do not. In other words, of the people who indicated that they believe 
fruit improves their symptoms of RA (n=13), 12 of them (92%) actually increase their intake of fruit 
in order to improve their symptoms. Similarly, Figure 3.20 illustrates the distribution of those who 
actively avoid the type of food they believe worsens their symptoms and those who do not. In both 
cases, an apparent trend seems to occur with the majority of people following their own beliefs or 
advice regarding what they personally believe in terms of the impact food has on their symptoms 
except for in the case of gassy cooldrinks where only half (n=6; 54.5%)of participants avoid it. 
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Figure 3.19. Distribution of those who increased, vs. those who did not increase, their 
intake of the foods they believed improve their symptoms of RA 
 
 
Figure 3.20. Distribution of those who avoided, vs. those who did not avoid, the foods they 
believed worsen their symptoms of RA 
 
In terms of nutritional supplements, sixty four percent of participants (n=161) thought that 
nutritional supplements or complementary and alternative medicines (CAM) and therapies could 
improve their symptoms of RA (Figure 3.21). Calcium (n=90; 55.9%), vitamin D (n=83; 51.6%), folic 
acid (51.6%) and omega-3 FA (n=67; 41.6%) were believed to be the most beneficial (Figure 3.22) 
and other forms of CAM and therapies believed to be beneficial included glucosamine (n=12; 
7.5%), chondroitan (n=10; 6.2%), proanthocyanidin (n=6; 3.7%) acupuncture (n=10; 6.2%), 
homeopathy (n=10; 6.2%) and chiropractor (n=7; 4.3%) (Figure 3.23). Those who did not 
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recognise the names of these supplements answered “don’t know” when asked if they believed 
them to be beneficial in RA. A comparison between age and the belief of whether or not nutritional 
supplements or CAM  and therapies improved their symptoms of RA showed that those who 
responded that it could not improve their symptoms were slightly older (56.9 years vs. 55.0 years) 
but this did not reach statistical significance (p=0.6997).  
 
Figure 3.21. Distribution of responses regarding nutritional supplements or complementary 
and alternative medicines and therapies can improve symptoms of RA 
 
 
Figure 3.22. Nutritional supplements thought to improve symptoms of RA (n=161) 
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Figure 3.23. Complementary and Alternative Medicines and Therapies thought to improve 
symptoms of RA (n=161) 
 
Ninety eight percent (n=246) of participants used nutritional supplements (prescribed or not 
prescribed) in order to treat and improve their symptoms of RA. Two hundred and thirty eight 
participants (95% of those who used nutritional supplements) used nutritional supplements which 
were prescribed by their rheumatologist to treat their RA. The most frequently prescribed 
supplements (Figure 3.24) included folic acid (n=218; 91.6%), calcium (n=182; 76.5%) and vitamin 
D (n=185; 77.7%). Seventy four participants (29%) used nutritional supplements which were not 
prescribed by their rheumatologist to treat their RA (Figure 3.25) with omega-3 FA (n=48; 64.9%), 
multivitamin and minerals (n=22; 29.7%), calcium (n=22; 29.7%), vitamin B complex (n=15; 20.3%) 
and vitamin D (n=15; 18.9%) being used most frequently. Thirty seven participants (15%) reported 
using other forms of CAM such as glucosamine (n=9; 24.3%), chondroitan (n=8; 21.6%), silicon 
(n=4; 10.8%) and proanthocyanidin (n=2; 5.4%). Only eight persons reported using alternative 
therapies, including massage (n=3), chiropractor (n=1), acupuncture (n=1), magnets (n=1), 
hydrotherapy (n=1), homeopathy (n=1), reflexology (n=1) and reiki (n=1). Thirty one percent of 
participants (n=78) spent money on purchasing nutritional supplements and other forms of CAM 
and therapies.   The amount of money spent is depicted in Figure 3.26 with 55.1% (n=43) of these 
participants spending between R0 and R100 per month, 14.1% (n=11) between R101 and R200 
per month and 9.0% (n=7) spending as much as between R501 and R1000 per month.  
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Figure 3.24. Prescribed supplement use of RA patients (n=238) 
 
 
Figure 3.25. Non-prescribed supplement use of RA patients (n=74) 
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Figure 3.26. Amount of money spent by RA patients on nutritional supplements and other 
forms of complementary and alternative medicines and therapies 
 
No relationship was seen with education level and the use of nutritional supplements (p=0.3210). A 
trend was seen in that those who used CAM had a higher education level (tertiary education); 
although it did not reach statistical significance (p=0.0514). A significant difference was however 
seen in the use of alternative therapies and education level where those with tertiary education 
were the highest users (p=0.0068). 
 
3.5 MEDICATION 
Ninety percent (n=226) of the participants believed that medication could improve their symptoms 
of RA while eight percent (n=20) responded that they did not believe medication improved their 
symptoms and two percent (n=5) did not know.  Ninety nine percent (n=247) of the participants 
used medication and the medication used in all but one participant was prescribed by their 
rheumatologist. Ninety four percent (n=237) claimed to always take their medication as prescribed 
and four percent (n=11) of participants used medication for their RA which was not prescribed by 
their rheumatologist such as Arthrexin (Indomethacin) (n=6) which is an over the counter anti-
rheumatic, anti-inflammatory agent. Eighty two percent (n=205) used various types of prescribed 
pain medication (Figure 3.27 and 3.28), 60% (n=150) used prescribed NSAIDS (Figure 3.29 and 
3.30), 97% (n=243) used prescribed DMARDS (Figure 3.31 and 3.32), and 9% (n=23) used 
prescribed biologic agents (Figure 3.33 and 3.34). The differences in use of certain medications 
between the public and private sectors are discussed in more detail in section 3.7.4. 
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Figure 3.27. Types of pain medication used for all participants (n=205) 
 
 
Figure 3.28. Types of pain medication used for public and private sectors (n=205) 
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Figure 3.29. Types of non-steroidal anti-inflammatory drugs used (n=150) 
 
 
Figure 3.30. Types of non-steroidal anti-inflammatory drugs used for public and private 
sectors (n=150) 
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Figure 3.31. Types of disease modifying anti-rheumatic drugs used (n=243) 
 
 
Figure 3.32. Types of disease modifying anti-rheumatic drugs used for public and private 
sectors (n=243) 
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Figure 3.33. Types of biologic agents used (n=23) 
 
Figure 3.34. Types of biologic agents used for public and private sectors (n=23) 
 
Seventy eight percent (n=195) used corticosteroids such as prednisone and cortisone. Of those 
195 participants who were prescribed corticosteroids, 154 (79%) participants had another co-
morbid disease (Table 3.4). Fifty one percent (n=99) of those using corticosteroids presented with 
hypertension and only four percent (n=7) presented with osteoporosis. The use of corticosteroids 
did not seem to show a relationship with a simultaneous presence of hypertension or osteoporosis 
as these statistics are not significant (p=0.39932; p=0.33479 respectively). The use of 
corticosteroids also had no statistically significant effect on the self-reported weight gain 
experienced (p=0.49051), waist circumference categories (p=0.33881), percentage body fat 
categories (p=0.95904) or fat mass index categories (p=0.05464). 
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Of those 195 participants who were prescribed corticosteroids, 165 participants (85%) were also 
prescribed calcium supplements, 167 participants (86%) were prescribed vitamin D supplements 
and 163 participants (84%) were prescribed a combination of both calcium and vitamin D 
supplements. The composition and doses of the specific supplements were not recorded.  
Table 3.4. Frequency of additional co-morbidities in those RA patients receiving 
corticosteroids 
 No. of 
participants 
% of those receiving 
corticosteroids 
p-value 
Heart Disease 13 7% 0.11995 
Hypertension 99 51% 0.39932 
Osteoarthritis 50 26% 0.52188 
Diabetes Mellitus 22 11% 0.95911 
Osteoporosis 7 4% 0.33479 
 
Eighteen percent (n=46) of participants had medical aid of which most (n=40; 15.9%) were from 
the private sector and 6 participants (2.4%) from the public sector. Of those who had medical aid, 
29 participants (63%) reported that the medical aid covered all their medication costs. For those 
who did not have medical aid or those who had to pay in an amount every month to cover their 
medication costs, the amount of money spent on medication is depicted in Figure 3.35. 
 
 
Figure 3.35. Distribution of amount of money spent on medication by patients per month 
(n=222) 
 
3.6 EXERCISE 
Seventy one percent (n=178) of the participants reported that they exercised, with most (n=139; 
78.1%) performing cardiovascular exercise (walking, swimming, cycling, etc.) (Figure 3.36) 
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Figure 3.36. Different types of exercise performed (n=178) 
 
The mean total minutes per week spent on doing exercise was 241.6 minutes/week (±SD:173.6). 
The exercise categories were distributed as shown in Figure 3.37. Myself/internal motivation (67%; 
n=120), rheumatologists/doctor (19%; n=34), physiotherapist/biokineticist (12%; n=21), and family 
or friends (7%; n=12) were the highest given responses to who suggested that they do exercise. 
Seventy six percent (n=136) of those who did exercise stated that they exercised specifically to 
improve their symptoms of RA. 
 
Figure 3.37. Distribution of exercise intensity and amount categories (n=178) of participants 
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3.7 PUBLIC VERSUS PRIVATE SECTORS 
3.7.1 Demographics and Patient Characteristics 
When comparing the public and private sectors, statistical differences were seen in the distribution 
of race, where the public sector consisted mostly of coloured South Africans and the private sector 
consisted mostly of Caucasian South Africans (p<0.0001). The two groups were comparable in 
terms of age and duration of disease with no statistically significant differences seen (p=0.13 and 
p=0.44 respectively). Smokers/previous smokers vs. non-smokers reached near significance 
where the public sector comprised of more smokers/previous smokers (p=0.0620). Of the 
smokers/previous smokers, the public sector smoked for a mean of 27.5 years vs. a mean of 18.8 
years in the private sector (p=0.0104). In terms of education level, the private sector consisted of 
56% who attained tertiary education vs. 5% in the public sector (p<0.0001) and the public sector 
consisted of 6% with no education and 24% with primary school education compared to the private 
sector where all participants reached at least secondary school level (p<0.0001). 
 
3.7.2 Body Composition 
The differences in mean values for the private sector and public sector, with men and women 
analysed separately, are shown in Table 3.5. There was a significant difference in mean height 
between the two groups in females (1.57m in public sector vs. 1.62 in the private sector; 
p=0.0001). No overall differences between males and females were seen in mean weight, BMI and 
waist circumference except for the males, where a significant difference was seen in BMI 
(25.9kg/m2 in public sector vs. 30.3 in private sector; p=0.0461). Percentage body fat did not differ 
between the two sectors when comparing males and females separately nor when comparing the 
categories of percentage body fat for males and females separately (p=0.4891 and p=0.1979 
respectively). Absolute fat mass and fat mass index in men did not differ (p=0.9688 and p=0.9020 
respectively) when comparing private versus public sector. Absolute fat mass and fat-free mass did 
however differ in the females, where the private sector had a higher fat mass (p=0.0243) and fat-
free mass (p=0.0134).  
 
Table 3.5. Mean values for anthropometrical measurements for the public versus private 
sectors. 
Participants 
Anthropometrical 
measurement 
(Mean values) 
Public sector Private Sector p-value 
All participants BMI (kg/m2) 29.8 29.1 0.748355 
Females Weight (kg) 76.2 76.4 0.729321 
 
Height (m) 1.57 1.62 0.000067 
 
BMI (kg/m2) 30.7 28.9 0.195674 
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Participants 
Anthropometrical 
measurement 
(Mean values) 
Public sector Private Sector p-value 
 
WC (cm) 91.8 89.5 0.392367 
 
TSF Average (mm) 19.1 21.5 0.176366 
 
BSF Average (mm) 8.7 10.6 0.061523 
 
SISF Average (mm) 16.1 17.3 0.553125 
 
SSSF Average (mm) 19.2 19.0 0.979951 
 
Sum of SF (mm) 63.0 68.3 0.450897 
 
% Body fat 33.4 35.1 0.114519 
 
Fat mass (kg) 20.9 24.7 0.024341 
 
Fat-free Mass (kg) 40.8 44.4 0.013404 
 
Fat Mass Index (kg/m2) 8.4 9.4 0.054861 
 
Fat-free Mass Index 
(kg/m2) 16.4 16.9 0.144957 
Males Weight (kg) 75.2 89.7 0.054479 
 
Height (m) 1.70 1.72 0.553128 
 
BMI (kg/m2) 25.9 30.3 0.046054 
 
WC (cm) 91.3 100.7 0.091148 
 
TSF Average (mm) 9.1 11.6 0.332635 
 
BSF Average (mm) 5.0 5.9 0.789268 
 
SISF Average (mm) 12.9 18.1 0.256016 
 
SSSF Average (mm) 14.0 14.4 0.713258 
 
Sum of SF (mm) 40.9 50.0 0.442264 
 
% Body fat 21.1 24.5 0.616291 
 
Fat mass (kg) 14.9 19.8 0.332635 
 
Fat-free Mass (kg) 53.0 58.6 0.132751 
 
Fat Mass Index (kg/m2) 5.2 6.8 0.367054 
 
Fat-free Mass Index 
(kg/m2) 18.4 20.3 0.066149 
BMI= Body Mass Index; WC= Waist Circumference; TSF= Triceps Skinfold; BSF= Biceps Skinfold; SISF= Supra-Ileac 
Skinfold; SSSF= Subscapular Skinfold; SF= Skinfold 
 
3.7.3 Diet, Nutritional Supplements, Complementary and Alternative Medicines and 
Therapies 
No differences were seen between the two groups in terms of their opinion regarding whether or 
not foods improved or worsened their symptoms of RA (p=0.0962 and p=0.5849 respectively) nor 
whether or not they avoided certain foods they believe worsened their symptoms of RA or 
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increased their intake of foods they believed could improve their symptoms (p=0.7034 and 
p=0.3377). 
No differences were seen in the opinion regarding whether or not nutritional supplements and other 
forms of complementary and alternative medicines or therapies improved their symptoms of RA 
(p=0.7318), as well as the use of nutritional supplements (p=0.9964). A large difference was 
however seen in the overall use of non-prescribed nutritional supplements in the private sector 
(68%) vs. only 20% in the public sector (p<0.0001) with a higher use in the private sector of 
calcium (47% vs. 15%; p=0.0024), magnesium (18% vs. 3%; p=0.0215) and multivitamin and 
mineral supplements (47% vs. 15%; p=0.0024). No difference was seen in the use of prescribed 
nutritional supplements although there was a higher percentage of public participants who were 
prescribed calcium (91% vs. 15%; p<0.0001) and vitamin D (90% vs. 26% p<0.0001). A slight 
difference in the overall use of complementary and alternative medicines was seen with a trend of 
higher use in the private sector (24% vs. 13%; p=0.0514) and a higher use of glucosamine (50% 
vs. 12%; p=0.0116), and chondroitan (42% vs. 12%; p=0.0400) in the private sector. A definite 
difference was seen with a higher overall use of complementary and alternative therapies in the 
private sector (10% vs. 1%; p=0.0073). A large difference was also seen in whether or not the 
participants spent money on nutritional supplements and other forms of complementary and 
alternative medicines or therapies with 76% in the private sector and 20% in the public sector 
(p<0.0001).  
 
3.7.4 Medication 
The majority of the private sector participants (80%) had medical aid compared to only 3% in the 
public sector (p<0.0001) and 90% of those without medical aid or whose medical aid did not cover 
all their expenses in the public sector did not pay anything for their medication compared to 8% in 
the private sector (p<0.0001). Large differences were seen in the types of medication used (see 
Figures 3.28, 3.30, 3.32 and 3.34). The public sector used pain medication overall more frequently 
than the private sector (92% vs. 42%; p<0.0001) with a higher use of paracetemol in the public 
sector (97% vs. 57%; p<0.0001). A higher use of certain pain medication was however seen in the 
private sector, namely, tramacet (tramadol and paracetemol) (43% vs. 1%; p<0.0001), adcodol 
(paracetemol, codeine phosphate, caffeine and doxylamine succinate) (5% vs. 0%; p=0.0320) and 
dextroproxyphene (5% vs. 0%; p=0.0320). The private sector used anti-inflammatory medication 
overall more frequently than the public sector (72% vs. 57%; p=0.0447) with a higher use of 
arcoxia (etoricoxib) (8% vs. 0%; p=0.0031), piroxicam (6% vs. 0%; p=0.0161), coxflam 
(meloxicam) (44% vs. 0%; p<0.0001), and celebrex (celecoxib) (22% vs. 0%; p<0.0001). The 
public sector however had a higher use of diclofenac (98% vs. 17%; p<0.0001). A higher use of 
corticosteroids was seen in the public sector (84% vs. 52% p<0.0001). No difference was seen in 
the overall use of DMARDS. A higher use of certain DMARDS was however seen in the public 
sector, namely, Sulfasalazine (28% vs. 13%; p=0.0207), chloroquine (66% vs. 29%; p=0.0001), 
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and azothioprine (6% vs. 0%; p=0.0258). The private sector had a higher use of leflunomide (6% 
vs. 0%; p=0.0017). A large difference was seen in the use of biologic agents with 46% of the 
private sector compared to 0% of the public sector (p<0.0001). 
 
3.7.5 Exercise 
No differences were seen in exercise behaviour (p=0.2081), amount of exercise or intensity level of 
exercise (p=0.3599) between the two groups. There was however a difference in opinion regarding 
whether or not exercise improved their symptoms of RA, where the public sector was more likely 
than the private sector to answer ‘yes’ when asked if they think exercise can improve their 
symptoms (80% vs. 64%; p=0.0476). 
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4. DISCUSSION 
 
A satisfactory study population size was obtained, which came very near to the pre-calculated 
sample size required. Although the private sector participant numbers specifically, that were 
reached, were lower than the calculated number, this group was still large enough to detect 
significant differences between the private and public sectors. 
 
The nutritional status of RA has previously been determined to be poor.46,84,102,104 This study looked 
at the body composition and anthropometrical status of RA patients and the results are very 
disturbing. Firstly, the presence of obesity and high waist circumference values are unacceptably 
elevated. These figures are much higher than the study conducted in Cape Town, South Africa by 
Mody et al111 in 1989 where obesity was seen in only 10.5% of the RA patients. In this study 
population, obesity according to BMI, was seen in almost half of the participants and a FMI of >90th 
percentile was seen in almost a third of non-obese participants according to BMI. Thus, when BMI 
and FMI were both used to classify obesity, the figures were even higher at more than half of 
participants being classified as obese. A possible reason for the increased obesity statistics 
compared to 1989 could be due to the overall increase of obesity in the general population 
worldwide.126 A number of reasons are thought to contribute to this increase including changes in 
diet (easily accessible food and a more palatable diet) and decreased physical activity due to 
increased reliance on cars and mechanical manufacturing.126 A review conducted in 2006 identified 
other possible reasons for the increase in obesity; namely insufficient sleep, endocrine disruptors 
(environmental pollutants which interfere with lipid metabolism), decreased rates of smoking 
(smoking suppresses appetite), and increased use of medications that can cause weight 
gain.113,126,127 Another reason for the high rates of obesity is that South Africa has a very high 
obesity prevalence in general, especially among Black women and Caucasian men.123,124 This 
could possibly also contribute to the development of RA in South Africa due to an increased 
susceptibility of obese individuals to develop RA.5 Central obesity was also present in this study. 
More than half of the participants had a waist circumference which showed a substantially 
increased risk for the development of metabolic complications and almost a quarter showed an 
increased risk. These statistics again mirror the general population in South Africa which has a 
high prevalence of central obesity.123,124 These findings are also consistent with the findings in 
other studies where central obesity was found in more than half the study population.73,109 In terms 
of body fat percentage, more than half of the participants and two thirds of women had an 
unhealthily high BF percentage classification.  These statistics highlight a threatening problem in 
the body composition of these RA patients. It is worrying that in a national study conducted by the 
researcher and other authors in 2007128, 68% (n=15) of South African rheumatologists referred 
less than 10% of their patients to a dietitian and 27% (n=6) referred 10-30% of their patients.128 
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It is necessary to try to determine the reasons for the poor anthropometrical status in these 
patients in order to correct the problem and to provide improved treatment for these patients. The 
literature described earlier has indicated a number of reasons for the poor nutritional status seen in 
RA patients, the most obvious being the inability of some RA patients to exercise due to disability, 
the reduced range of movement they experience and pain.1,2,8,9 However, a high percentage of 
participants indicated that they exercised and more than half exercised at a self-reported moderate 
intensity for 150 to 300 minutes a week or more, which may, in the light of the high obesity 
statistics, be a case of over-reporting by the participants.  Another reason for the poor nutritional 
status could be due to medication side effects. Corticosteroids have been shown to cause weight 
gain and the effect of DMARDS and biologics could possibly also have an effect on weight gain.8,33  
 
With regards to rheumatoid cachexia, it is very apparent that looking at BMI alone is not 
appropriate in RA patients because the concurrent presence of a low fat-free mass and a high fat 
mass seen in RA patients cannot be detected with BMI alone.73,109 This is illustrated in this 
population by the fact that all patients who presented with rheumatoid cachexia were classified 
according to BMI as underweight (1%), normal (7%) or overweight (3%) and not obese. These 
patients would appear to be in a reasonably good nutritional status when in fact they were very 
malnourished. The 2007 study by the researcher and other authors showed that 68% (n=15) of 
South African rheumatologists said that their patients were generally of normal weight and 32% 
(n=7) said their patients were overweight.128 These statistics highlight a possible discrepancy 
between the perceptions of rheumatologists regarding the nutritional status of their patients and the 
actual nutritional status of their patients.128 The 2007 study was however a national sample, 
whereas this study was a provincial sample and it is possible (and probably more plausible) that 
the Cape Metropolitan area in the Western Cape could have more obese RA patients compared to 
other provinces. In fact, the 1998 and 2003 SADHS studies both reported that overweight, obesity 
and mean waist circumference measurements seen in the general population were highest in the 
urbanized provinces of Western Cape, KwaZulu-Natal and Gauteng.113 A nationwide study on 
nutritional status in RA patients is needed to investigate if this is true for the RA population too. 
 
When looking at the differences seen in the private and public sector, it is interesting to note that 
the private sector women were taller than those in the public sector. This could be due to the fact 
that in this study, the private sector participants are better educated than the public sector and it 
has been shown that taller men and women are those with the highest education level, while those 
without education are the shortest.113 
 
An increased risk of CVD already exists among patients with RA and a high prevalence of 
modifiable risk factors for CVD such as hypertension, smoking, obesity and high waist 
circumference values (indicating central obesity) was seen in this study population which could 
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potentially increase the risk for CVD even further.15 More than half of the population were smokers 
or previous smokers. Smoking is not only a risk factor for the development of heart disease but 
also may influence the risk of developing RA and may negatively influence the course of the 
disease.4,5,11 Brady et al16 found that when compared to controls, RA patients had higher mean 
BMI and waist circumference measurements and were more likely to be smokers. The mean 
absolute risk of CVD was significantly higher in the RA group (p=0.036) even after excluding 
smokers.16 This RA study has also shown a prevalence of high BMI and waist circumference 
values. Not only do the RA patients exhibit the presence of CVD risk factors, but many of them 
have a combination of CVD risk factors. A combination of hypertension together with high waist 
circumference, obesity or smoking was each seen in a third of participants. Since CVD is the 
leading cause of mortality in RA, it stands to reason that this is a problem which requires urgent 
attention.25 The monetary cost of RA is already high and with the additional co-morbidities, the cost 
of the burden of disease is exacerbated.15,31  
 
The effect of diet on the symptoms of RA have been said to be highly individualised and this has 
been confirmed in this study, with mixed results on perception of what improves or worsens the 
symptoms of the RA patients. An informal observation the investigator made when collecting the 
data is that most of the time, each individual felt quite strongly about whether or not diet affected 
their symptoms and which foods were responsible. Diet may have a role to play in alleviating 
symptoms but this is a very complex subject in RA. The improved symptoms seen in clinical 
studies may be due to the change from an unhealthy diet to a healthier diet with increased fruit and 
vegetable consumption and reduced saturated fats content.77 The perception of the participants 
that fruits and vegetables improve their symptoms may be due to this fact. The red meat, 
tomatoes, spices, etc. which participants said worsens their symptoms could be due to underlying 
and perhaps undiagnosed conditions such as gout. The effects of dietary manipulation require 
further studies to confirm the benefits of specific diets in order to make specific 
recommendations.77 
 
Patients with RA should follow an individualized, healthy, balanced diet.45 In general, the diet 
recommended for arthritis is similar to that of good health with special emphasis on cardiovascular 
risk prevention.45,70 Due to the increased risk for CVD and osteoporosis in RA patients, 
preventative dietary measures should be followed to prevent dyslipidaemia and enforce weight 
control.15,18,20,46 Nutritional supplementation should be considered in patients who struggle to meet 
their requirements through diet alone and in those on medications which have known drug-nutrient 
interactions such as folic acid supplementation with Methotrexate use.45,46 Those with osteoporosis 
for example, should meet their dietary recommendations for calcium intake from dietary sources 
where possible and calcium and vitamin D supplementation in older patients, particularly if 
housebound and/or in those with a poor dietary intake.18 Certain diets (such as fasting, elimination, 
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and elemental diets) have shown potential in improving symptoms but these diets cannot be 
regarded as standard dietary treatment.80 They may however be of use in certain individual 
patients.  
 
The majority of the RA patients were taking nutritional supplements either prescribed or non-
prescribed. The supplements which were prescribed most frequently by rheumatologists (folic acid, 
vitamin D and calcium) were appropriate in methotrexate and corticosteroid use in order to 
counteract the drug-nutrient interactions seen in these drugs and prevent possible side effects. 
Guzman-Clark et al129 reported that only 32% of patients on long term glucocorticoid treatment 
were prescribed calcium supplements.129 This study shows that almost all patients on 
corticosteroids were also prescribed calcium and vitamin D to prevent osteoporosis which is very 
satisfactory. It is well known that omega-3 FA supplementation reduces inflammatory markers and 
decreases the need for NSAIDS and DMARDS.81,82,83 Omega-3 FA were not prescribed by any of 
the rheumatologists but this is probably due to the fact that it does not have a code that can be 
used to claim the costs back from medical aid providers.  It is however possible that they 
recommend it to their patients. The 2007 study by the researcher and other authors showed that 
sixty four percent (n=14) of South African rheumatologists indicated that they prescribe 
supplements.128 The three most common supplements that these rheumatologists prescribed/ 
recommended were omega 3 FA (71%; n=10), calcium (57%; n=8) and vitamin B complex (29%; 
n=4).128  
 
The difference seen in the private and public sectors in the use of non-prescribed nutritional 
supplements, complementary and alternative medicines and alternative therapies (with a higher 
use in the private sector) is most likely due to the high costs of these supplements, medicines and 
therapies which those in the public sector cannot afford. A study conducted in Canada showed that 
high household income, high level of education and being food-secure were positively associated 
with supplement use and this could be true for this population too.130 The use of complementary 
and alternative supplements and therapies has become a growing and ever more popular field, 
especially within population groups suffering from a chronic disease such as RA.63 Fifteen percent 
of the participants reported using complementary and alternative medicines such as glucosamine, 
chondroitan and proanthocyanidin. The beneficial effects of these CAM have however not been 
conclusively confirmed.65,70,73  Some studies show that glucosamine and chondroitan may be 
beneficial in osteoarthritis. A recent meta-analysis has however shown no benefit.71 More studies 
are therefore needed to confirm this potential beneficial effect in osteoarthritis.71 Furthermore, no 
beneficial effect has been shown in RA patients.72 If further studies show a benefit in osteoarthritis, 
then there is the potential that patients with RA and concurrent osteoarthritis may see some benefit 
but this will need to be explored in experimental studies. Until studies are conclusive however, 
patients are wasting their money on expensive and seemingly ineffective CAM in addition to the 
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already high medical costs they incur. It is very important that RA patients are educated and 
informed on this issue and the dietitian has a very important role in achieving this. 
 
Medication, such as what is used in this RA population (NSAIDs, Methotrexate, corticosteroids, 
etc.), can have an effect on nutritional status by altering nutrient absorption, metabolism, utilization 
or excretion of certain nutrients.41 RA patients are in particular vulnerable to these effects as they 
are at risk of developing drug induced deficiencies due to inadequate diets and increased 
nutritional needs due to chronic illness.46,84  It is very important that dietitians are aware of the drug-
nutrient interactions which exist with the medication used in RA. Universities which offer dietetics 
need to ensure that training on RA is delivered in their courses and that they pay special attention 
to these drug-nutrient interactions. 
 
In the public sector in South Africa, doctor’s consultations, medication and treatment is provided 
free of charge or at a minimal cost for those who cannot afford medical aid for private care. Those 
in the public sector therefore do not incur high costs for their treatment. Those on private care 
however incur very high expenses for the medication that medical aid does not cover as well as the 
expense of monthly medical aid payments which cover private doctors’ fees and can be thousands 
of rand per month. The differences in use of certain medications seen between the private and 
public sector are due to the costs of the medication and budgetary constraints in the public sector. 
Biologics are much more expensive than traditional DMARDs and therefore are not currently used 
in the public sector. This is an issue which needs to be addressed. Biologics have the potential to 
dramatically improve the quality of life for those who have failed at treating their disease with 
traditional DMARDs and should become less expensive in order for more patients to benefit. 
Patients, rheumatologists, government, medical aids and pharmaceutical companies need to work 
together to make this treatment accessible to all RA patients who need it. The consequences of RA 
include loss of employment, reduced social functioning and significant healthcare costs and the 
economic burden of RA is thought to be substantial for people with RA as well as the relevant 
health services.27,31 Perhaps if more patients were treated with the appropriate medication, a direct 
saving on long term healthcare costs and indirect savings with increased ability to work and 
function would warrant the spending of local governments on better medications. A cost-benefit 
and cost-effectiveness study is warranted to investigate this scenario. 
 
In terms of medication use in the private sector, it must be mentioned that the high number of 
patients on tocilizumab and golilumab in this study population does not necessarily represent 
typical SA biologics use, but is influenced by fact that the rheumatologists in the private sector 
were participating in trials using these agents, which were not registered for use in SA at the time 
of the study. Tocilizumab is now registered as actemra and is available to SA patients. 
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The null hypothesis of this study was that there are no differences in terms of body composition, 
diet and medication use between the private and public sector participants. This null hypothesis 
can therefore be rejected as differences were seen between the two groups; mainly due to direct 
(costs of medication, supplements, etc.) and indirect (disadvantaged background, poor eating 
habits) socio-economic factors. 
 
The main limitation to this study is that it was a descriptive study and the level of some of the 
evidence is therefore limited. The analytical component of the study does however strengthen the 
findings. Further limitations include the fact that no biochemical markers were measured to 
determine nutritional status. Although skinfolds are an accurate measure of calculating body 
composition, it would have been more accurate to use Dual X-Ray Absorptiometry (DEXA). DEXA 
could also have been used to measure bone density and therefore screen for and diagnose 
osteoporosis in these RA patients.112 DEXA however has little epidemiological applicability 
because of the high costs and methodological efforts required for its use in a study. The predictive 
equations derived from skinfold measurements provide good associations with fat mass estimation 
compared with the reference methods and are preferred in a research setting because of its lower 
costs and methodological effort.121 The smaller size of the private sector group was also a 
limitation but the study population was large in total and this smaller group was still large enough to 
detect significant differences between the two groups. Concerning the patient’ supplement intake 
of omega-3 FA, micronutrients and other forms of CAM, the exact doses and frequency of intake 
and whether or not the supplements were a combination of different nutrients (eg. omega-3 and 
omega-6 FA) was not recorded. 
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
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5. CONCLUSIONS AND RECOMMENDATIONS 
RA is a devastating disease with a potentially profound effect on the quality of life of those who live 
with it.27 Any measure that can be taken in an attempt to improve their symptoms and quality of life 
should be addressed. The risk factors for CVD and the high obesity seen in this population are 
problems which need to be urgently addressed. The role of dietitians in this regard is vital.  The 
fact that malnutrition in RA patients can be underlying and not obvious to the eye is all the more 
reason that all RA patients, not just the obese, should at least be assessed and further consulted if 
necessary by a dietitian. The dietitian should be involved in ensuring that the patient receives 
proper nutrition with enough protein and micronutrients and supplementation if appropriate and 
necessary. Reaching an ideal body composition and maintaining an ideal body weight will not only 
improve the symptoms of RA but also decrease the risk for developing cardiovascular disease and 
therefore improve their prognosis.15,16,45 Educating the patient on healthy eating and appropriate 
supplementation and addressing the problem of unproven CAM use is also very important. The 
successful, timely management of patients with RA depends on the involvement of a range of 
health care professionals, according to the individual patient’s needs. An intra-professional 
approach is very important and includes not only the dietitian but also physiotherapists and 
occupational therapists that can work out exercise regimens and improve the range of movement 
as well as increase physical activity levels. Support groups are another important part of improving 
the quality of life of persons with RA and can serve as an access to this patient group for targeted 
education and initiatives. Government, pharmaceutical companies, rheumatologists and medical 
aids should work together to create more awareness about RA and evidence-based practice in 
order to limit debilitation and to increase quality of life for these patients. 
 
Recommendations for future studies include nationwide research on nutritional and 
anthropometrical status of RA patients in order to determine if the high obesity seen in this study is 
prevalent in the rest of the country. Future studies should also include biochemical markers to 
detect the micronutrient status of RA patients in SA as well as the dietary intake in order to 
determine a complete picture of the nutritional status of RA patients. Studies should look at the 
possibility that the presence of food allergies could exacerbate RA symptoms. Experimentally 
controlled studies relating to the effects of different types of diets (e.g. elimination, vegan, fasting, 
etc.) on the symptoms of RA and which patients are likely to benefit the most are needed. Another 
area for research is the effects of supplementation with antioxidants and other micronutrients as 
well as nutritional supplements such as chondroitin, glucosamine, gamma linolenic acid and 
proanthocyanidin.  
 
In conclusion, this study highlights that it is very clear how important the role of the dietitian is in 
the management of RA and can undoubtedly improve the quality of life and symptoms, decrease 
overall medical costs and deliver improved standards of care for those living with RA. 
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Addendum A. Questionnaire – English 
Questionnaire 
BODY COMPOSITION OF RHEUMATOID ARTHRITIS PATIENTS AND THEIR PERCEPTIONS 
AND PRACTICES REGARDING DIET, NUTRITIONAL SUPPLEMENTS AND OTHER 
TREATMENTS. 
 
A . Personal information  
1. Date of birth:  ___________________________________ 
2. Sex:   Female (F)  Male (M)  
3. Rheumatoid Arthritis duration:  ____________________________________________ 
4. Any other diseases/conditions present?  Yes (y)   No (n) 
4.1. If yes, specify:  
HPT  Hyperchol  DM OA Gastric SE  HD 
_______________________________________________________________________________
_______________________________________________________________________________ 
5. Any diagnosed food allergies/ history of food allergies?  Yes   No 
5.1. If yes, specify:  
Please tick appropriate box(es) 
 Fish 
 Seafood 
 Peanuts 
 Milk 
 Wheat 
 Eggs 
 Tree nuts 
 Soya 
 Other, 
specify:_____________ 
 
6. Have you lost or gained any weight since you have been diagnosed with RA?  Yes   No 
6.1. If yes, brief weight loss/gain history: 
_______________________________________________________________________________
_______________________________________________________________________________ 
7. Are you a smoker/ previous smoker?    Yes   No 
7.1. If yes, for how many years? 
_______________________________________________________________________________
_______________________________________________________________________________ 
8.  What is your highest level of education? 
 Grade: ________ (1-12) 
 Degree/Diploma (13) 
 Postgraduate degree (14) 
 No education (15) 
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B. Perceptions and Practices 
1. Do you think certain foods improve your symptoms?   Yes (y)   No (n)   Don’t know (d) 
1.1. If yes, which foods do you think improve your symptoms?  
Please tick appropriate box(es) 
 Wholewheat products 
 Refined carbohydrates (white bread, pastries, etc)  
 Sugar 
 Dairy and dairy products (yogurt, cheese, etc.) 
 Fruit 
 Vegetables  
 Red meat 
 Chicken & Poultry 
 Fish 
 Seafood (other than fish) 
 Spices 
  Tomatoes 
 Alcohol, specify:_________________________ 
 Other, specify:__________________________
 
2. Do you think certain foods worsen your symptoms?  Yes   No   Don’t know  
2.1. If yes, which foods do you think worsen your symptoms?  
Please tick appropriate box(es)
 Wholewheat products 
 Refined carbohydrates (white bread, pastries, etc)  
 Sugar 
 Dairy and dairy products (yogurt, cheese, etc.) 
 Fruit 
 Vegetables  
 Red meat 
 Chicken & Poultry 
 Fish 
 Seafood (other than fish) 
 Spices 
  Tomatoes 
 Alcohol, specify:_________________________ 
 Other, specify:__________________________
 
3. Do you avoid certain foods that you think might make your symptoms worse?  Yes   No 
3.1. If yes, which foods? 
Please tick appropriate box(es)
 Wholewheat products 
 Refined carbohydrates (white bread, pastries, etc)  
 Sugar 
 Dairy and dairy products (yogurt, cheese, etc.) 
 Fruit 
 Vegetables 
 Red meat 
 Chicken & Poultry 
 Fish 
 Seafood (other than fish) 
 Spices 
  Tomatoes 
 Alcohol, specify:_______________________ 
 Other, specify:__________________________
 
3.2. If yes, do you replace that type of food with any other type of food or supplement in order to 
replace the nutrients of the food you have excluded?  Yes   No 
3.3. If yes, specify: 
_______________________________________________________________________________
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_______________________________________________________________________________
_______________________________________________________________________________ 
 
4. Do you increase your intake of any specific foods to improve your symptoms?   Yes   No 
4.1. If yes, specify:  
 Wholewheat products 
 Refined carbohydrates (white bread, pastries, etc)  
 Sugar 
 Dairy and dairy products (yogurt, cheese, etc.) 
 Fruit 
 Vegetables 
 Red meat 
 Chicken & Poultry 
 Fish 
 Seafood (other than fish) 
 Spices 
  Tomatoes 
 Alcohol, specify:_______________________ 
 Other, specify:__________________________
 
5. Do you think medication can improve your symptoms?  Yes   No  Don’t know 
 
6. Do you use any medication to treat your Rheumatoid Arthritis?  Yes   No 
6.1. If yes, which medications?  
Please tick appropriate box(es) 
 Pain medication (Paracetemol, Aspirin, Morphine, Codeine, etc.) 
 Steroids (Cortisone, Prednisone etc.) 
 NSAIDS (Diclofenac (Voltaren), Ibuprofen, Celecoxib, etc.) 
 DMARDS (Methotrexate, Azathioprine, Chloroquine, Golimumab, Leflunomide Cyclphosphamide, Cyclosporin, 
etc.) 
 Biologic agents 
 
6.2. Is the medication prescribed by your doctor/ rheumatologist?  Yes   No 
 
6.3. Do you always take the medication which is prescribed to you by your doctor/ rheumatologist?       
 Yes   No 
6.3.1. If no, how often do you NOT take the medication? Specify: 
___________________________________________________________________________
___________________________________________________________________________ 
6.4. Do you use any medication which has not been prescribed by your doctor/ rheumatologist?              
 Yes   No 
6.4.1. If yes, specify: 
___________________________________________________________________________
_____________________________________________________________ 
7. Do you think nutritional supplements can improve your symptoms?  Yes   No  Don’t know 
7.1. If yes, which nutritional supplements do you think improve your symptoms?  
Please tick appropriate box(es) 
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  Omega – 3 Fatty Acids 
 Calcium 
 Vitamin D 
 Folic acid 
 B – Carotenoids 
 Vitamin B complex 
 Selenium 
 Zinc 
 Magnesium 
 Niacin 
 Other, specify:__________________________ 
 
8. Do you take any nutritional supplements to treat your Rheumatoid Arthritis?  Yes   No 
8.1. If yes, specify:  
Please tick appropriate box(es)
 Omega – 3 Fatty Acids 
 Calcium 
 Vitamin D 
 Folic acid 
 B – Carotenoids 
 Vitamin B complex 
 Selenium  
 Zinc 
 Magnesium 
 Niacin 
 Other, specify:__________________________
 
9. Have you ever heard of or know what complementary and alternative medicines or therapies (such as 
Glucosamine, Chondroitan, Gamma Linolenic Acid, Homeopathy, Chiropractor or Acupuncture) is?    Yes   No 
9.1. If yes, Do you think complementary and alternative medicines or therapies can improve your 
symptoms?  
 Yes   No  Don’t know 
9.1.1. If yes, which complementary and alternative medicines or therapies do you think can 
improve your symptoms?  
Please tick appropriate box(es)
 Glucosamine 
 Chondroitan 
 Gamma Linolenic Acid 
 Thunder God Vine 
 Valerian  
 Zinaxin 
 Plant-Mineral Preparations 
 Chiropractor 
 Acupuncture 
 Magnets 
 Hydrotherapy 
 Homeopathy 
 Other, specify:__________________________ 
 None of the above 
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10. Do you take any of the following complementary and alternative medicines/ supplements? 
Please tick appropriate box(es)  
  Glucosamine 
 Chondroitan 
 Gamma Linolenic Acid 
 Thunder God Vine 
 Valerian 
 Zinaxin 
 Plant-Mineral Preparations 
 Other, specify:___________ 
 None of the above
 
11. Do you use any of the following alternative therapies? 
Please tick appropriate box(es)  
 Chiropractor 
 Acupuncture 
 Magnets 
 Hydrotherapy 
 Homeopathy 
 Other, specify:__________________________ 
 None of the above 
 
12. How much do you spend on nutritional supplements per month?  
Please tick appropriate box 
 Nothing (1)  
 R0-100 (2) 
R101-200 (3) 
R201-300 (4) 
R301-400 (5) 
R401-500 (6) 
R501-1000 (7) 
R1001-2000 (8)    
R2001-3000 (9) 
R3001-4000 (10)      
 >R4000 (11)   
 Other, 
specify:______
 
13. How much do you spend on complementary and alternative medicines and therapies per month? 
Please tick appropriate box 
 Nothing (1)  
 R0-100 (2) 
R101-200 (3) 
R201-300 (4) 
R301-400 (5) 
R401-500 (6) 
R501-1000 (7) 
R1001-2000 (8)    
R2001-3000 (9) 
R3001-4000 (10)      
 >R4000 (11)   
 Other, 
specify:______
         
14. Do you have medical aid?  Yes   No 
14.1. If yes, does the medical aid cover all your medication expenses?  Yes   No 
14.2. If no, how much do you spend on medication per month? 
Please tick appropriate box 
 Nothing (1)  
 R0-100 (2) 
R101-200 (3) 
R201-300 (4) 
R301-400 (5) 
R401-500 (6) 
R501-1000 (7) 
R1001-2000 (8)    
R2001-3000 (9) 
R3001-4000 (10)      
 >R4000 (11)   
 Other, 
specify:______
 
15. Do you do any exercise?  Yes   No 
15.1. If yes, what type of exercise do you do? 
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Please tick appropriate box(es) 
   Resistance exercise (weights) 
  Cardiovascular exercise (running, walking, swimming, cycling, etc.) 
  Stretching 
  Physio/ OT exercises  
  Pilates 
  Yoga 
 Other, specify:______________________________________ 
 
15.2. How often do you exercise? 
Please tick appropriate box 
 1 x month (1) 
 2 x month (2) 
 3 x month (3) 
 1 x week (4) 
 2 x week (5) 
 3 x week (6) 
 4 x week (7) 
 5 x week (8) 
 6 x week (9) 
 Everyday (10) 
 
15.3. For how long at a time do you exercise? 
Please tick appropriate box 
 10-20 mins 
 20-30 mins 
 30-40 mins 
 40-60 mins 
 60-90 mins 
 >90 mins 
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15.4. Who suggested to you that you do exercise? 
  Doctor/ Rheumatologist 
 Myself/ Internal motivation 
 Physiotherapist/ Biokineticist 
 Dietitian 
 Family or friends 
 Other, specify:______________________________________ 
 
15.5. Do you do exercise specifically to improve your symptoms of RA?  Yes   No 
15.6. If no, why do you do exercise?_________________________________________________  
 
THANK YOU FOR YOUR PARTICIPATION ☺ 
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For Office Use Only: 
Comorbidities/ Medical history of note: 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________ 
 
Prescribed Medication (Type & Dosage): 
MTX 
Folate 
Chloroquine 
Sulfasalazide 
Prednisone/Cortisone 
Voltaren 
Ibuprofen 
Paracetemol 
Codeine 
Asprin 
Vit D 
Ca 
Amitryptiline 
Radaq 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________ 
 
MEASUREMENT TYPE MEASUREMENTS TAKEN                     
Weight (kg)    
Height (cm)    
Waist Circumference (cm)    
Triceps skinfold (mm)    
Biceps skinfold (mm)    
Supra-ileac skinfold (mm)    
Subscapular skinfold (mm)    
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Addendum B. Questionnaire - Afrikaans  
Vraestel 
 
LIGGAAM SAMESTELLING VAN RUMATOÏEDE ARTRITIS PASIENTE EN HULLE 
PERSEPSIES EN PRAKTYKE MET BETREKKING TOT DIEET, VOEDINGSAANVULLINGS EN 
ANDER BEHANDELINGS. 
 
A . Persoonlike informasie  
9. Geboorte datum:  ___________________________________ 
10. Geslag:   Vroulik  Manlik 
11. Rumatoïede Artritis diagnosis datum:  ____________________________________________ 
12. Enige ander toestande/ siektes teenwoordig?  Ja   Nee 
12.1. Indien Wel, Spesifiseer:  
HPT  Hyperchol  DM OA Gastric SE  HD 
_______________________________________________________________________________
_______________________________________________________________________________ 
13. Enige gediagnoseerde voedsel allergië/ geskiednis van voedsel allergië?  Ja   Nee 
13.1. Indien Wel, Spesifiseer:  
Merk af asseblief die korrekte blok(ke) 
 Vis 
 Seekos 
 Grondboontjies 
 Melk 
 Koring 
 Eiers 
 Neute 
 Soja 
 Ander, 
Spesifiseer:_____________ 
 
14. Het u enige gewig verloor of opgetel sedert u diagnosis met RA?  Ja   Nee 
14.1. Indien Wel, kortlikse gewigsverlies/optel geskiedenis: 
_______________________________________________________________________________
_______________________________________________________________________________ 
15. Is u ‘n roker/ vorige roker?    Ja   Nee 
15.1. Indien Wel, vir hoeveel jaar? 
_______________________________________________________________________________
_______________________________________________________________________________ 
16. Wat is u hoogste vlak van opvoeding? 
 Graad: _________________ 
 Graad/ Diploma 
 Nagraadse Graad 
 Geen opvoeding 
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B. Persepsies en Gewoontes 
 
16.  Dink u dat sekere kos u simptome kan verbeter?   Ja   Nee   Weet nie 
16.1. Indien Wel, wat se kos dink u sal jou simptome verbeter?  
Merk af asseblief die korrekte blok(ke) 
 Volkoring produkte 
 Verfynde Koolhidrate (witbrood, pasteie, ens)  
 Suiker 
 Suiwel en Suiwel produkte (jogurt, kaas, etc.) 
 Vrugte 
 Groente  
 Rooi vleis 
 Hoender 
 Vis 
 Seekos (Anders as Vis) 
 Speserye 
  Tamaties 
 Alkohol, 
Spesifiseer:_________________________ 
 Ander, 
Spesifiseer:__________________________
 
17. Dink u dat sekere kos jou simptome vererger?  Ja   Nee   Weet nie  
Indien Wel, wat se kos dink u vererger jou simptome?  
Merk af asseblief die korrekte blok(ke)
 Volkoring produkte 
 Verfynde Koolhidrate (witbrood, pasteie, ens)  
 Suiker 
 Suiwel en Suiwel produkte (jogurt, kaas, etc.) 
 Vrugte 
 Groente  
 Rooi vleis 
 Hoender  
 Vis 
 Seekos (Anders as Vis) 
 Speserye 
  Tamaties 
 Alkohol, 
Spesifiseer:_________________________ 
 Ander, 
Spesifiseer:__________________________
 
18. Vermy u sekere kos wat u dink mag jou simptome vererger?  Ja   Nee 
18.1. Indien Wel, wat se kos? 
Merk af asseblief die korrekte blok(ke)
 Volkoring produkte 
 Verfynde Koolhidrate (witbrood, pasteie, ens)  
 Suiker 
 Suiwel en Suiwel produkte (jogurt, kaas, etc.) 
 Vrugte 
 Groente 
 Rooi vleis 
 Hoender  
 Vis 
 Seekos (Anders as Vis) 
 Speserye 
  Tamaties 
 Alkohol, 
Spesifiseer:_______________________ 
 Ander, 
Spesifiseer:__________________________
18.2. Indien Wel, vervang u daadie tipe kos met enige ander tipe kos of aanvulling om die verlore 
nutriente te vervang?  Ja   Nee 
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18.3. Indien Wel, Spesifiseer: 
_______________________________________________________________________________
_______________________________________________________________________________
__________________________________________________________ 
19. Verhoog u jou inname van enige spesifieke kos om jou simptome te verbeter?   Ja   Nee 
19.1. Indien Wel, Spesifiseer:  
 Volkoring produkte 
 Verfynde Koolhidrate (witbrood, pasteie, ens)  
 Suiker 
 Suiwel en Suiwel produkte (jogurt, kaas, etc.) 
 Vrugte 
 Groente 
 Rooi vleis 
 Hoender 
 Vis 
 Seekos (Anders as Vis) 
 Speserye 
  Tamaties 
 Alkohol, 
Spesifiseer:_______________________ 
 Ander, 
Spesifiseer:__________________________
 
20. Dink u dat medikasie u simptome kan verbeter?  Ja   Nee  Weet nie 
 
21. Gebruik u enige medikasie om jou Rumatoïede Artritis te behandel?  Ja   Nee 
21.1. Indien Wel, watter medikasies?  
Merk af asseblief die korrekte blok(ke) 
 Pyn medikasie (Paracetemol, aspirin, morphine, codeine, etc.) 
 Steroids (Cortisone, Prednisone etc.) 
 NSAIDS (Diclofenac (Voltaren), Ibuprofen, Celecoxib, etc.) 
 DMARDS (Methotrexate, Azathioprine, Chloroquine, golimumab, lefluNeemide Cyclphosphamide, Cyclosporin, 
etc.) 
 Biologiese agente 
 
21.2. Is die medikasie voorgeskryf deur jou dokter/ rumatoloog?  Ja   Nee 
 
21.3. Neem u gereeld die medikasie wat voorgeskryf is deur jou doktor/ rumatoloog altyd in?  Ja   Nee 
21.3.1. Indien Nie, hoe gereeld neem u die medikasie nie in nie? Spesifiseer: 
___________________________________________________________________________
___________________________________________________________________________ 
21.4. Gebruik U enige medikasie wat nie voorgeskryf is deur jou doktor/ rumatoloog?     Ja   Nee 
21.4.1. Indien Wel, Spesifiseer: 
___________________________________________________________________________
_____________________________________________________________ 
 
22. Dink u dat voedingsaanvullings jou simptome kan verbeter?  Ja   Nee  Weet nie 
22.1. Indien Wel, wat se voedingsaanvullings dink u sal jou simptome kan verbeter?  
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Merk af asseblief die korrekte blok(ke) 
  Omega – 3 Vetsure 
 Calsium 
 Vitamien D 
 Folien suur 
 B – Caratonoids 
 Vitamien B compleks 
 Selenium 
 Sink 
 Magnesium 
 Niasien 
 Ander, 
Spesifiseer:__________________________ 
 
23. Neem u enige voedingsaanvullings om jou Rumatoïede Artritis te behandel?  Ja   Nee 
23.1. Indien Wel, Spesifiseer:  
Merk af asseblief die korrekte blok(ke)
 Omega – 3 Vetsure 
 Calsium 
 Vitamien D 
 Folien suur 
 B – Caratonoids 
 Vitamien B compleks 
 Selenium 
 Sink 
 Magnesium 
 Niasien 
 Ander, 
Spesifiseer:__________________________ 
24. Het u al gehoor van, of weet u van komplimentere en alternatiewe medisyne of terapieë (soos 
Glucosamine, Chondroitan, Gamma Linolenic Acid, Homopatie, Kiropraktisyn or Akupunktuur) is?    Ja   Nee 
24.1. Indien Wel, dink u dat komplimentere en alternatiewe medisyne of terapieë jou simptome kan 
verbeter?  Ja   Nee 
24.2. Indien Wel, wat se komplimentere en alternatiewe medisyne of terapieë dink u kan jou simptome 
verbeter?  
Merk af asseblief die korrekte blok(ke)
 Glucosamine 
 Chondroitan 
 Gamma Linolenic Acid 
 Thunder God Vine 
 Valerian  
 Zinaxin 
 Plant-Minerale Preparations 
 Kiropraktisyn 
 Akupunktuur 
 Magnete 
 Hidroterapie 
 Homopatie 
 Ander, 
Spesifiseer:__________________________ 
 Geen van bogenoemde 
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25. Neem u enige van die volgende komplimentere en alternatiewe medisyne/ aanvullings? 
Merk af asseblief die korrekte blok(ke)  
 Glucosamine 
 Chondroitan 
 Gamma Linolenic Acid 
 Thunder God Vine 
 Valerian 
 Zinaxin 
 Plant-Mineral Preparations 
 Ander, 
Spesifiseer:_____________ 
 Geen van bogenoemde 
 
26. Gebruik u enige van die volgende alternatiewe terapieë? 
Merk af asseblief die korrekte blok(ke)  
 Kiropraktisyn 
 Akupunktuur 
 Magnete 
 Hidroterapie 
 Homopatie 
 Ander, 
Spesifiseer:__________________________ 
 Geen van bogenoemde 
 
27. Hoeveel spandeer u aan voedingsaanvullings per maand? 
Merk af asseblief die korrekte blok 
 Niks  
 R0-100  
R101-200 
R201-300 
R301-400 
R401-500  
R501-1000  
R1001-2000      
R2001-3000 
R3001-4000       
 >R4000    
 Ander, 
Spesifiseer:______
 
28. Hoeveel spandeer u aan komplimentere en alternatiewe medisyne en terapieë per maand? 
Merk af asseblief die korrekte blok 
 Niks  
 R0-100  
R101-200 
R201-300 
R301-400 
R401-500  
R501-1000  
R1001-2000      
R2001-3000 
R3001-4000       
 >R4000    
 Ander, 
Spesifiseer:______ 
         
29. Het u ‘n mediese fonds?  Ja   Nee 
29.1. Indien Wel, dek die mediese fonds al jou medikasie uitgawes?  Ja   Nee 
29.2. Indien Nie, hoeveel spandeer U aan medikasie per maand? 
Merk af asseblief die korrekte blok 
 Niks  
 R0-100  
R101-200 
R201-300 
R301-400 
R401-500  
R501-1000  
R1001-2000 
R2001-3000 
R3001-4000       
 >R4000    
 Ander, 
Spesifiseer:______
30. Doen u enige oefening?  Ja   Nee 
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30.1. Indien Wel, watter tipe oefening doen u? 
Merk af asseblief die korrekte blok(ke) 
   Weerstand oefeninge (gewigte) 
  Kardiovaskulere oefening (hardloop, stap, swem, fietsry, ens.) 
  Strek oefeninge 
  Fisio/ OT oefenings  
  Pilates 
  Yoga 
 Ander, Spesifiseer:______________________________________ 
 
30.2. Hoe gereeld doen u oefening? 
Merk af asseblief die korrekte blok(ke) 
 1 x maand 
 2 x maand 
 3 x maand 
 1 x week 
 2 x week 
 3 x week 
 4 x week 
 5 x week 
 6 x week 
 Elke dag 
 
30.3. Vir hoe lank op ‘n slag oefen u? 
Merk af asseblief die korrekte blok(ke) 
 10-20 mins 
 20-30 mins 
 30-40 mins 
 40-60 mins 
 60-90 mins 
 >90 mins 
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30.4. Wie het oefening aan jou voorgestel?  
  Dokter/ rumatoloog 
 Self/ Interniese motiveering 
 Fisioterapeut/ Biokinetikus 
 Dieetkundige 
 Familie of vriende 
 Ander, Spesifiseer:______________________________________ 
 
30.5. Oefen u spesifiek om  jou simptome van RA te verbeter?  Ja   Nee 
30.6. Indien Nie, waarom oefen jy?_________________________________________________  
 
DANKIE VIR U DEELNAME ☺ 
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For office use only: 
Comorbidities/ Medical history of Neete: 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________ 
 
Prescribed medication (Type & Dosage): 
MTX 
Folate 
Chloroquine 
Sulfasalazide 
Prednisone/Cortisone 
Voltaren 
Ibuprofen 
Paracetemol 
Codeine 
Asprin 
Vit D 
Ca 
Amitryptiline 
Radaq 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________ 
 
MEASUREMENT TYPE MEASUREMENTS TAKEN                     
Weight (kg)    
Height (cm)    
Waist Circumference (cm)    
Triceps skinfold (mm)    
Biceps skinfold (mm)    
Supra-ileac skinfold (mm)    
Subscapular skinfold (mm)    
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Addendum C. Consent form – English 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
Body composition of rheumatoid arthritis patients and their perceptions and practices regarding diet, 
nutritional supplements and other treatments. 
 
REFERENCE NUMBER: ___________ 
 
PRINCIPAL INVESTIGATOR: 
Louise Lombard  
Registered Dietician 
Master of Nutrition student 
 
ADDRESS: 
Division of Human Nutrition 
Faculty of Health Sciences 
Stellenbosch University 
Tygerberg Campus  
 
CONTACT NUMBER: 
021 913 6504 
0829022281 
 
Dear participant 
 
You are being invited to take part in a research project.  Please take some time to read the information 
presented here, which will explain the details of this project.  Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary and you are free to decline to participate.  If you say no, this will not affect 
you negatively in any way whatsoever.  You are also free to withdraw from the study at any point, even if you 
do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the international Declaration of 
Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
What is this research study all about? 
 The study will be conducted at Tygerberg Hospital, Groote Schuur Hospital and at a few private 
practices in the Cape Metropolitan area. There will be a total of about 250 participants. 
 The study aims to determine the body composition of rheumatoid arthritis patients in the private and 
public health sector in the Cape Metropole as well as their perceptions and practices regarding the 
use of diet, nutritional supplements, medication, complementary and alternative medicines/ 
therapies and exercise in the treatment of the disease. This will gather important and useful 
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information that will help rheumatologists, dietitians and any other healthcare professional in treating 
rheumatoid arthritis optimally. 
 You will need to answer a few questions that the researcher will ask you about your diet, the use of 
nutritional supplements, medication, any other complementary and alternative medicines or 
therapies you may be using and exercise.  
 Then we will be measuring your weight, height, waist and hip circumference and skinfolds. The 
skinfolds are measured by using callipers that look like tongs. It might pinch a little but it will not hurt 
you. The measurements will be taken by a professional and qualified dietician in a private and 
confidential room where no one will be able to see you.  
 We will also need to access your medical records, with your permission, in order to obtain 
information about your medical history, other health conditions and the medication you are on.  
 The questionnaire will only take approximately 10-15 minutes to complete and approximately 15 
minutes for the measurements to be taken. The total amount of time will therefore not be longer than 
30 minutes. 
 
Why have you been invited to participate? 
 You have been invited to partake in this study because you have rheumatoid arthritis. 
 
What will your responsibilities be? 
 You will need to sign this consent form which details all the particulars of the study as explained to 
you and state that you give your permission for us to gather the information and use it for the 
research study. 
 You will need to answer the questions as explained to you above and allow us to take the 
measurements. 
 
Will you benefit from taking part in this research? 
 You will not benefit financially from this research project, but you will benefit in an indirect way since 
your participation will be of paramount importance in gathering the much needed information that 
rheumatologists, dieticians and other healthcare professionals need to treat rheumatoid arthritis 
optimally and make a difference in the lives of RA patients. 
 
Are there in risks involved in your taking part in this research? 
 There are no risks involved. 
 
Who will have access to your medical records? 
 Only the researcher will have access to your medical records. 
 The information collected will be treated as confidential and protected and your identity will always 
remain anonymous.   
 
What will happen in the unlikely event of some form of injury occurring as a direct result of your taking 
part in this research study? 
 There are no risks involved in partaking in this research project.  
 
Will you be paid to take part in this study and are there any costs involved? 
 No you will not be paid to take part in the study. There will be no costs involved for you, if you do 
take part. 
Is there anything else that you should know or do? 
 You can contact Lisanne du Plessis at tel 021 9389175 if you have any further queries or encounter 
any problems. 
 You can contact the Committee for Human Research at 021-938 9207 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
By signing below, I (name)…………………………………..…………. agree to take part in a research study 
entitled “Body composition of rheumatoid arthritis patients and their perceptions and practices regarding diet, 
nutritional supplements and other treatments”. 
. 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised to take 
part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or researcher feels it 
is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2011. 
 
 
 
 ............................................................................   .........................................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign the 
declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2011. 
 
 
 
 ............................................................................   .........................................................................  
Signature of investigator Signature of witness 
 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to explain the information 
in this document to (name of participant) ……………..…………………………….. using the 
language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
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Signed at (place) ......................…........…………….. on (date) …………....………………2011.. 
 
 
 
 ............................................................................   .........................................................................  
Signature of interpreter Signature of witness 
  
 
Stellenbosch University  http://scholar.sun.ac.za
 107 
 
Addendum D. Consent form - Afrikaans  
DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
 
 
TITEL VAN DIE NAVORSINGSPROJEK: 
Liggaam samestelling van Rumatoïede artritis pasiente en hulle persepsies en praktyke met betrekking tot 
dieet, voedingsaanvullings en ander behandelings. 
 
VERWYSINGSNOMMER: ___________ 
 
HOOFNAVORSER: 
Louise Lombard  
Geregistreede Dieetkundige 
Meester Voeding student 
 
KONTAKNOMMER: 
021 913 6504 
0829022281 
ADRES: 
Divisie Menslike Voeding 
Fakultyd van Gesondheidswetenskappe 
Stellenbosch Universiteit 
Tygerberg Kampus 
 
 
 
U word genooi om deel te neem aan ’n navorsingsprojek.  Lees asseblief hierdie inligtingsblad op u tyd deur 
aangesien die besonderhede van die navorsingsprojek hierin verduidelik word.  Indien daar enige deel van 
die navorsingsprojek is wat u nie ten volle verstaan nie, is u welkom om die navorsingspersoneel of dokter 
daaroor uit te vra.  Dit is baie belangrik dat u ten volle moet verstaan wat die navorsingsprojek behels en hoe 
u daarby betrokke kan wees.  U deelname is ook volkome vrywillig en dit staan u vry om deelname te 
weier.  U sal op geen wyse hoegenaamd negatief beïnvloed word indien u sou weier om deel te neem nie.  
U mag ook te enige tyd aan die navorsingsprojek onttrek, selfs al het u ingestem om deel te neem. 
 
Hierdie navorsingsprojek is deur die Etiek Komitee oor Gesondheidsnavorsing van die Universiteit 
Stellenbosch goedgekeur en sal uitgevoer word volgens die etiese riglyne en beginsels van die 
Internasionale Verklaring van Helsinki en die Etiese Riglyne vir Navorsing van die Mediese 
Navorsingsraad (MNR). 
 
Wat behels hierdie navorsingsprojek? 
 Die studie sal uitgevoer word by  Tygerberg Hospitaal, Groote Schuur Hospitaal en by ‘n paar 
privaat praktyke in die Kaapse Metropolitaanse gebied. Daar gaan omtrent ‘n totaal van 250 
deelnemers wees. 
 Die studie se doel is om die ligaam samestelling van Rumatoïede artritis pasiente in die privaat en 
publieke gesondheids sektor in die Kaapse Metropolitaan te ondersoek asook hulle persepsies en 
praktyke met betrekking tot dieet, voedingsaanvullings, medikasie, komplimentere en alternatiewe 
medisyne of terapieë en oefening in die behandeling van die siekte. Dit sal belangrik en nuttige 
informasie insamel wat rumatoloë, dieetkundiges en enige ander gesondheids professioneel sal help 
in die optimale behandelling van Rumatoïede artritis. 
 Dit is nodig dat u ‘n paar vrae beantwoord wat die navorser gaan vra oor u dieet, die gebruik van 
voedingsaanvullings, medikasie, komplimentere en alternatiewe medisyne of terapieë dat U dalk 
gebruik en beoefening. 
 Ons gaan dan u gewig, lengte, middelomtrek en velvoue mates neem. Die velvoue word gemeet 
met ‘n kaliper wat soos ‘n tang lyk. Dit gaan dalk ‘n bietjie knyp maar dit sal jou nie seer maak nie. 
Die meetings gaan deur ‘n professionele en gekwalifiseerde dieetkundige geneem word in ‘n privaat 
en konfidensiele kamer waar niemand jou sal kan sien nie. 
 Ons gaan ook met jou toestemming, toegang tot jou mediese rekords nodig hê om die informasie 
oor jou mediese geskiedenis, ander gesondheidskondisies en die medikasie wat u neem te verkry. 
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 Die vraestel sal net omtrent 10-15 minute neem om te voltooi en ongeveer 15 minute om die 
meetings te neem. Die totale tydperk sal dus nie langer as 30 minute duur nie. 
 
Waarom is u genooi om deel te neem? 
 U is genoooi om deel te neem aan hierdie studie omdat u Rumatoïede artritis het. 
 
Wat sal u verantwoordelikhede wees? 
 U sal hierdie toestemmings vorm moet teken wat al die besonderhede van die studie soos vir jou 
verduidelik is en verklaar dat u toestemming gee  vir ons om die informasie saam te stel en te 
gebruik vir die navorsing studie.  
 U sal die vrae moet antwoord soos bo verduidelik en ons die metings laat neem.  
 
Sal u voordeel trek deur deel te neem aan hierdie navorsingsprojek? 
 U sal nie finansieel voordeel trek van hierdie narvorsing projek nie maar U sal wel in ‘n indirekte 
manier voordeel trek aangesien U deelneme van kardinale belang is in die versamaleling van 
informasie wat baie nodig is vir rumatoloë, dieetkundiges en enige ander gesondheids professionele 
om Rumatoïede artritis optimaal te behandel en ‘n verskil te kan maak in die lewens van RA 
pasiente. 
 
Is daar enige risiko's verbonde aan u deelname aan hierdie navorsingsprojek? 
 Daar is geen risiko betrokke. 
 
Wie sal toegang hê tot u mediese rekords? 
 Slegs die navorser sal toegang hê tot u mediese rekords. 
 Die informasie wat versamel is sal konfidensieel behandel word en U identiteit sal altyd anoniem bly.   
 
Wat sal gebeur in die onwaarskynlike geval van ’n besering wat mag voorkom as gevolg van u deelname 
aan hierdie navorsingsprojek? 
 Daar is geen risikos betrokke in die deelneme van hierdie narvorsing projek.  
 
Sal u betaal word vir deelname aan die navorsingsprojek en is daar enige koste verbonde aan 
deelname? 
 
 U sal nie betaal word vir deelname aan die navorsingsprojek nie. Deelname aan die 
navorsingsprojek sal u niks kos nie. 
 
Is daar enigiets anders wat u moet weet of doen? 
 
 U kan Lisanne du Plessis kontak by tel 021 9389175  indien u enige verdere vrae het of enige 
probleme ondervind. 
 U kan die Etiek Komitee oor Gesondheidsnavorsing kontak by 021-938 9207 indien u enige 
bekommernis of klagte het wat nie bevredigend deur u studiedokter hanteer is nie. 
 U sal ’n afskrif van hierdie inligtings- en toestemmingsvorm ontvang vir u eie rekords. 
 
 
Verklaring deur deelnemer 
Met die ondertekening van hierdie dokument onderneem ek, (naam) …….....................……….....……...……….., 
om deel te neem aan ’n navorsingsprojek getiteld  “Liggaam samestelling van Rumatoïede artritis pasiente en hulle 
persepsies en praktyke met betrekking tot dieet, voedingsaanvullings en ander behandelings”. 
 
Ek verklaar dat: 
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• Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat voorlees het en dat dit in 
’n taal geskryf is waarin ek vaardig en gemaklik mee is. 
• Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend beantwoord is. 
• Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat daar geen druk op 
my geplaas is om deel te neem nie. 
• Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige wyse daardeur 
benadeel sal word nie. 
• Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is indien die 
studiedokter of navorser van oordeel is dat dit in my beste belang is, of indien ek nie die 
ooreengekome navorsingsplan volg nie. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2011. 
 
 
 
 ............................................................................   .........................................................................  
Handtekening van deelnemer Handtekening van getuie 
 
 
Verklaring deur navorser 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
• Ek die inligting in hierdie dokument verduidelik het aan 
…………………….............................................……….. 
• Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
• Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo bespreek, 
voldoende verstaan. 
• Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik is, moet die tolk die 
onderstaande verklaring teken.) 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2011. 
 
 
 
 ............................................................................   .........................................................................  
Handtekening van navorder Handtekening van getuie 
 
 
Verklaring deur tolk 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
• Ek die navorser (naam) ……….............................…………………. bygestaan het om die inligting 
in hierdie dokument in Afrikaans/Xhosa aan (naam van deelnemer) 
……………………………......................... te verduidelik. 
• Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
• Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
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• Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle verstaan en dat al 
sy/haar vrae bevredigend beantwoord is. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2011. 
 
 
 
 ............................................................................   .........................................................................  
Handtekening van tolk Handtekening van getuie 
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